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ABSTRACT
Production of Recombinant Human BRCAl Encoded Proteins in E.coli.
Berna S. Ozpelik
M.S. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Oztiirk 
August 1997,137 pages
Among the risk factors that cause breast cancer, heredity emerges as the major 
determinant. BRCAl is the first gene which was found to be associated with inherited 
early-onset breast cancer. BRCAl is spread over a 100 kb region on human chromosome 
17q21 and consists of 22 coding exons which are transcribed into a 7.8 kb long mRNA. 
This mRNA is abundant in breast and ovarian tissues and encodes a polypeptide of 1863 
amino acids. The exact cellular function of BRCAl remains to be elucidated. As there are 
many gaps of knowledge and many conflicts about the cellular functions of BRCAl, new 
points of views and technical approaches should be generated. As such studies require the 
presence of purified protein products, we aimed to express and purify BRCAl encoded 
proteins. In this study we cloned the BRCAl gene in four overlapping fragments into the 
pCR-Script Amp, sk (+) cloning vector and subcloned the carboxyl terminal into the pQE 
expression vector. The 73 kD gene product was purified by affinity chromatography.
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ÖZET
İnsan BRCAl Rekombinant Proteininin E.coft*’de Üretilmesi
Berna S. Özçelik
Yüksek Lisans Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos 1997,137 sayfa
BRCAl geni, ailesel, genç yaşta baş gösteren meme kanseri ile ilişkisi olduğu 
saptanan ilk gendir ve onyedinci kromozomda yer almaktadır. 3RCA1 geni 17. 
kromozomun q kolunda 100 kilobazlık bir alana yayılmıştır. 24 ekzonu vardır ve bunlardan 
22 tanesi transkripsiyon ile 7.8 kilobaz uzunluğunda bir mRNA kodlar. Bu mRNA’mn en 
bol memede ve överde bulunduğu ve translasyonu sonucu 1863 amino asit uzunluğunda 
bir polipeptid oluştuğu saptanmıştır. BRCAl proteininin hücredeki rolü henüz tam olarak 
bilinmemektedir. BRCAl’in hücredeki işlevleri hakkında pek çok bilgi eksikliği ve 
çelişkiler mevcut olduğundan, yeni bakış açılanmn ve tekniklerin geliştirilmesi gereklidir. 
Bu tip çalışmalarda saflaştınimış proteine ihtiyaç duyulduğundan, çalışmalarımızı bu yöne 
yönlendirdik. Bu çalışmada BRCAl genini dört kesişen fragman halinde pCR-Script Amp, 
SK (+) vektörüne ve karboksil terminalini bir ekspresyon vektörüne klonladık. 73 
kilodaltonluk bir ekspresyon ürününü afinite kromatografi ile saf bir şekilde izole ettik.
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CHAPTER I
INTRODUCTION
1-1 GENERAL INTRODUCTION
Breast cancer is one of the most common fatal malignancies affecting females in 
developed countries. It is estimated that one of eight women will develop breast cancer 
by age 95 (Miki et a i, 1994). In United States more than 180,000 new cases were 
observed in 1996, and each year about 45,000 women die of breast cancer in this country 
(Parker et al., 1996). The etiology of breast cancer involves a complex interplay of 
genetic, endocrine, and dietary factors that are superimposed on the physiological status 
of the host. Among these risk factors family history emerges as the major determinant 
(Schildkraut et al., 1989). Studies have shown that genetic factors contribute to 
approximately 5- to 10- % of all cases but 25% of cases diagnosed before age 30 (Claus 
et. al., 1991). The two breast cancer susceptibility genes identified (BRCAl and 
BRCA2) are believed to be responsible for more than 80% of familial cases diagnosed 
before age 80 (Ford et al., 1994). Presence of a positive family history was observed 
even in sporadic cases and about one third of women with sporadic breast cancer have 
one or more first degree relatives having breast cancer (Marcus et al., 1996). Breast 
cancer is 100 times less frequent in man than women and it is also rare in young women 
(<20 years of age). Its frequency increases progressively from 20 to 45 years of age, 
stabilizes around 55 years, then increases abruptly in older age. About 85% of breast 
cancers occur after 40 years of age. Life style and dietary factors also contribute to
occurrence of breast cancer as secondary risk factors, that daily exercise and dietary 
intake of phytoestrogens are thought to decrease the risk of developing breast cancer 
(Knekt et a l, 1996). Controversially daily uptake of alcohol increases the risk of breast 
cancer by 40% (Holmberg et al., 1995). Treatment of advanced breast cancer is often 
pointless and disfiguring, making early detection very important by means of the medical 
management of the disease (Miki et al., 1994).
Breast cancer is a tumor of the mammaiy gland. The anatomy of breast is shown 
in figure 1-1. The breast tissue is composed 10-15 galactophorous channels. The 
mammary gland is formed by a surface epithelium attached to myoepithelial cells and 
continuously exposed to hormonal factors. The 17ß-estradiol (active estrogen) and 
progesterone play a critical role in the physiological regulation of mammary gland. 
Estrogen act mostly on the galactophours and induce mitotic activity of epithelial cells. 
The progesterone, which is secreted periodically, during the second phase of menstrual 
cycle, blocks mitotic activity induced by estrogens.
Breast tumors are classified as benign and malignant tuQiors. Among benign 
tumors, fibroadenomas are the most frequent forms of which develop before the age of 
30 years. They are characterized by a glandular proliferation localized with a variable 
fibrous component. More than 98% of malignant breast tumors are carcinomas and are 
classified according their histological features as shown in table 1-1.
In situ carcinomas can either be ductal or lobular, arising from the ductal 
epithelium or from the epithelium of the lobules, respectively. Non-infiltrating 
carcinomas occur in the epithelium of galactophour channels or the lobules. They do not 
infiltrate the neighboring connective tissues. They represent about 7% of breast 
carcinomas. Infiltrating carcinomas are mostly ductal carcinomas (70%). Paget disease is 
a carcinoma composed of large tumor cells infiltrating the epidermis of the nipple. They 
represent about 2% of breast cancers and they are associated to another mammary 
carcinomas (Rubin E., Färber J. L ).
Figure 1-1: The anatomy of the breast
Table 1-1: World Health Organization Classification of carcinomas (Rubin E., 
Färber J. L.)
Non-invasive Intraductal
Lobular carcinoma in situ 
Intraductal papillary carcinoma
Invasive Invasive ductal carcinoma
Paget's disease
Invasive lobular carcinoma
Medullary carcinoma
Mucinous carcinoma
Tubular well-differentiated carcinoma
Invasive papillary carcinoma
Adenoid cystic carcinoma
Secretory carcinoma
Apocrine carcinoma
Carcinoma with metaplasia
Mixed type______________________
1-2 MOLECULAR GENETICS OF BREAST CANCER
Development of cancer involves the activation of proto-oncogenes and the 
inactivation of tumor suppressor genes (Sager , 1989); (Weinberg, 1985). A schematic 
representation of the genetic alterations that take place in the progression from normal 
breast epithelium to metastatic carcinoma is shown in figure 1-2.
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Figure 1-2: Genetic alterations that take place in the progression from normal 
breast epithelium to metastatic carcinoma
Although multiple cytogenetic abnormalities have been detected in breast cancer, 
few abnormalities have been noted to be consistent. Results of cytogenetic and direct 
DNA studies have showed that the most commonly affected chromosomes were 1, 6, 8, 
13 and 17 (Wendy et al., 1990). These abnormalities include, amplification of 
oncogenes, point mutations, and loss of tumor suppressor genes.
Gene amplification results in an increase in the number of copies of a gene, which 
in turn leads to increased mRNA synthesis and increased protein production.
The oncogene c-erbB-l (HER-2 or neu) which is homologous to epidermal 
growth factor (EGF) is a cell surface growth factor receptor with receptor tyrosine 
kinase activity. Although it is not known whether the amplification of the erbB-2 gene 
plays a role in the initiation of mammary carcinogenesis, it was reported that it correlates 
with the aggressive behavior of breast cancer (Slamon et al., 1989). This gene is 
amplified in adenocarcinomas of a variety of organs, including breast, where the gene is 
amplified in approximately 28% of cases (Bems et al., 1995 ).
BCLl (cyclin D) is another oncogene that was found to be amplified in breast 
carcinomas. Overexpression of BCLl was observed at approximately 30% of breast 
cancers (Gillett et al., 1994). BCL2 is a gene involved in apoptosis that it functions as an 
inhibitor of apoptosis when overexpressed. Recently it was shown that the expression 
pattern of BCL2 and p53 was altered in approximately 33% of breast carcinomas 
(Siziopikou et al., 1996). Another study concerning the mutations in BCL2 and p53 
genes in male and female breast cancers showed that p53"/BCL2''· phenotype was more 
frequently seen in male breast cancers (Weber-Chappuis et al., 1996).
MDM2 is an oncogene which is transcriptionally transactivated by p53 tumor 
suppressor gene, and its elevated expression results in the downregulation of p53 activity 
(Momand et al., 1992) (Wu X. et al., 1993). Analysis of MDM2 and p53 expression 
levels in breast carcinoma cells showed that, at about 4 to 9% of breast tumors, MDM2 
expression levels were elevated up to 8 folds resulting in decrease in p53 expression 
levels (McCaim era/., 1995); (Marchetti etal., 1995).
Overexpression of c-myc by several mechanisms is found in a variety of different 
tumors (Vijer M. J., 1993). The myc nuclear proto-oncogene, located on chromosome 
8q24, was found to be amplified in about 6% to 33% and was found to be overexpressed 
in 17% primary breast tumors (Bems e ta i,  1995).
Some tumor suppressor genes involved in breast carcinomas were elucidated by 
loss of heterozygosity (LOH) assays. In breast cancers the most common deleted
regions include chromosome 5q21 (APC), 17p (p53), 17q21 (BRCAl), 13ql2-14 
(BRCA2 and Rb) and chromosome 10 (gene of Cowden Disease).
In a study of sporadic breast cancers (n=34), it was shown that 28% of the cases 
there was LOH in APC locus (5q21) (Thompson A. M., et al., 1993). ApcMin (Min, 
multiple intestinal neoplasia) is a point mutation in the murine homolog of the APC gene. 
Mice that are heterozygous for Min mutation (Min-/+) mice develop multiple intestinal 
adenomas, just like humans carrying germ-line mutations in APC. Female mice carrying 
the Min mutation are also prone to develop mammary tumors (Moser et al., 1993).
Tumor suppressor genes RB and p53 appear to be important in breast cancer 
(Stanbridge, 1990). The RB tumor suppressor gene codes for a nuclear DNA binding 
phosphoprotein which is phosphorylated and dephosphorylated in a cell cycle dependent 
manner and the phosphorylation is required for activation of a cell cycle dependent 
transcription activator, E2F (Wang et al., 1994). Inactivation of RB is observed in all 
retinoblastomas and in lesser proportion in other types of tumors, including breast 
carcinomas (Lee E. et al., 1988). In a study of 223 cases, loss of Rb expression was 
found at 21% of primary breast cancers (Anderson et al., 1996).
Like the RB protein, p53 is involved in the regulation of normal cell cycle and, 
when inactivated, leads to uncontrolled cell proliferation, leading to carcinogenesis. The 
p53 tumor supressor gene is localized to 17p and encodes 53 kD phosphoprotein with 
multiple important functions concerning cell fate, including cell cycle arrest, apoptosis 
and induction of DNA repair (Vogelstein B. et al., 1992); (Lee S. et al., 1995); (Smith 
M. L., et al., 1995). The p53 gene is the most commonly mutated gene in human tumors 
(Levine et al., 1991). Results of several studies have shown that incidence of breast 
cancer was increased in Li-Fraumeni Syndrome families (LFS) (Ford D. and Easton 
1995). LFS is a dominantly inherited syndrome in which family members are at high risk 
of developing a wide spectrum of tumors, including breast tumors, at an early age ( Li 
and Fraumeni, 1969). It is also shown that expression of mutant p53 increases from 13%
to 50% as breast cancers progress from early in situ to advanced metastatic lesions. This 
suggests that p53 mutation is an early event in breast cancer and is more common in the 
advanced forms (Davidoff et a i, 1991). Lindblom et ai, studied the LOH at p53 locus in 
82 familial breast carcinomas from 79 different families (Lindblom et al., 1993). Their 
results indicated that LOH in the p53 region was seen in 25-30% of breast cancer 
families, 40% of early-onset breast cancers and 10-15% of late-onset breast cancers 
(Lindblom e/a/., 1993).
Certain rare abnormalities of the androgen receptor located on the X 
chromosome appear to be associated with male breast cancer. Wooster et ai, identified 
a family in which two brothers with breast cancer had a constitutional mutation in the 
androgen receptor gene (Wooster et a l, 1992).
Breast cancer is also associated with autosomal dominantly inherited Cowden's 
disease and autosomal recessively inherited ataxia-telangiectasia (AT). AT is a rare 
disease in which homozygotes develop a progressive cerebellar ataxia, hypersensitivity 
to ionizing radiation, immune dysfunction and a striking predisposition to cancer (Swift 
et al., 1990). Heterozygotes for the disease also have an increased cancer incidence, 
with solid tumors of the breast, ovary, pancreas, stomach, and the bladder being most 
common (Swift et a i, 1987). Epidemiological studies have suggested that heterozygotes 
for the ataxia telangiectasia gene, AT, on chromosome 1 Iq are at elevated risk of breast 
cancer (Lynch et a l, 1994).
The overexpressed oncogenes/LOH at tumor suppressor genes and their 
participation to breast cancer are summarized in Table 1-2
S
Table 1-2: Oncogenes and TSGs involved in breast carcinomas
name of the gene participation to 
breast cancer (%)
reference
ONCOGENES
c-erbB-2 28 Berns et a i, 1995
BCL-1 30 Gillette étal., 1994
BCL-2 33 Siziopikou er a/., 1996
MDM2 4-9 McCann et al., 1995
c-myc 6-33 (amplification) 
17 (overexpression )
Berns er a/., 1995
TUMOR SUPRESSOR GENES
RB 21 Anderson et al., 1996
p53 25-30 Lindblom era/., 1993
APC 28 Thompson étal., 1993
BRCAl 50 (hereditary) Takahashi era/., 1995
BRCA2 35 (hereditary) Wooster era/., 1994
It is also reported that some tumor types co-segregate with breast cancer. 
Heterogeneity of breast cancer is illustrated in figure 1-2 (Lynch et a i, 1994).
Figure 1-3: Heterogeneity of breast cancer
(1: sporadic breast cases, 2: polygenic breast cancers, 3: breast and miscellaneous 
tumors, 4: extraordinarily early onset breast cancer, 5: breast/gastrointestinal cancer, 6: 
breast/ovarian cancer, 7; site-specific breast cancer, 8; breast cancer and LFS, 9: breast 
cancer and Cowden's disease)
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1-3 HEREDITARY FORMS OF BREAST CANCER
Although the incidence of breast cancer is estimated to be 1/9 for a woman over 
her lifetime, certain women appear to have an increased risk (Bowcock, 1993). Pedigree 
analysis suggest that 10% of all breast cancer cases are caused by an autosomal 
dominant mode of inheritance of breast cancer predisposition (Borresen, 1992). The first 
familial breast cancer was described by Paul Broca, more than a century ago and since 
then an enormous number of breast cancer-prone families have been reported (Lynch et 
a l, 1994).
The three important characteristics of familial breast cancers are the earlier age 
of onset than normal, presence of 3 or more first degree relatives suffering from breast 
cancer and the presenve of bilateral cancer. In 1988, it was shown that the risk of 
developing breast cancer for women who had a family history of the disease was 0.37 by 
age 40, 0.66 by age 55 and 0.82 over the entire lifetime. In contrast, risk of breast 
cancer in women without a family history was estimated to be 0.004 by age 40, 0.028 by 
age 55 and 0.081 over the entire lifetime. Females less than 15 years of age and males 
had a negligible risk (less than 0.001) (Newman et a l, 1988). These women who have 
increased risk harbor germ-line mutations that predispose to breast cancer susceptibility, 
and in general develop the disease at an earlier age. Such studies indicated the fact that
5-10% of breast cancer cases result from the inheritance of germline mutations in 
autosomal dominant susceptibility genes (Newman e ta l,  1988).
Two genes have been identified that are believed to play an important role in the 
familial form of breast cancer. BRCAl was the first locus associated with inherited 
early-onset breast cancer and was mapped to chromosome 17q21 by linkage analysis 
(Hall et a l, 1990). Subsequently it was shown that mutations in BRCAl were 
responsible for almost all families with multiple cases of both breast and ovarian cancer, 
and approximately 50 % of the families with breast cancer only (Easton et a l, 1993).
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There is also an increased risk for BRCAl carriers to develop prostate cancer (3%) in 
males and colon cancer (4%) in both males and females (Ford ei al, 1994). Another 
breast cancer susceptibility gene BRCA2 was found to be located on chromosome 
13ql2-13 by linkage analysis in 1994 (Wooster ei al., 1994). Mutations at this locus 
were also involved in the development and progression of breast cancer roughly as much 
as BRCAl but they do not appear to be associated with susceptibility to ovarian cancer 
although they are associated with cases of male breast cancer (Wooster et al., 1994).
BRCAl, BRCA2 and p53 germ-line mutations do not explain all of the familial 
cases. Therefore it is believed that there must be other genes predisposing to breast 
cancer.
1-4 BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENES
1-4.1 BRCAl
The first described breast and ovarian cancer susceptibility gene, BRCAl, was 
located to chromosome 17q-21 by linkage analysis (Hall et al., 1990) and then isolated 
in 1994 by Miki et al. by positional cloning strategies (Miki et al., 1994). The majority 
of breast cancer families with more than four affected members were linked to the 
BRCAl region, suggesting a high penetrance of this gene (Easton et al., 1993). BRCAl 
is spread over a 100 kb region on chromosome 17q and consists of 24 exons, 22 of 
which are transcribed into a 7.8 Kb long mRNA which is abundant in breast and ovary 
(Miki et al., 1994). Although alternatively spliced forms of the transcript have been 
identified the significance of the presence of these transcripts remain unknown (Lu et 
al., 1996), (Xu et al., 1995). The 7.8 Kb mRNA species encode a polypeptide of 1863 
amino acids which contains a 123 amino acid long RING finger domain at the N- 
terminus (Miki et al., 1994). Following the identification of the gene, mutation analysis
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of breast cancer families showed that germline mutations of BRCAl were responsible 
for approximately 50% of hereditary breast cancers (Friedman et a l, 1994). Somatic 
point mutations in BRCAl in sporadic tumors were found to be very rare (Futreal et a l, 
1994), but complete somatic deletion of one allele of BRCAl was identified to occur 
approximately 50% of sporadic breast cancers and 70% of sporadic ovarian cancers 
(Takahashi et a l, 1995). Approximately 85% of mutations that have been identified 
throughout the coding region of BRCAl give rise to truncated forms of protein that 
vary in length from 5% to 99% of full-length protein (Shattuck-Eidens et a l, 1995). 
Although any clustering of mutations had not been found, a founder effect had been 
observed in Ashkenazi Jewish families in which 185del AG mutation was frequently 
observed such that the carrier frequency of the BRCAl 185del AG mutation was 
approximately 1% among these individuals (Struewing et a l, 1995). In breast cancer 
patients who carry BRCAl predisposing alleles, observations have shown that 
malignancy results from the loss of the wild-type allele suggesting that BRCAl is a 
tumor suppressor (Neuhausen and Marshall, 1994). This hypothesis was supported by 
the identification of the fact that BRCAl negatively regulates the proliferation of 
mammary epithelial cells (Thompson et a l, 1995) and that transfection of MCF-7 breast 
cancer cell lines with wild-type BRCAl inhibits tumor progression (Holt et a l, 1996). In 
1996 Chen et a l  identified that BRCAl is a 220 kD nuclear phosphoprotein and in 
1997, BRCAl was found to be located in perinuclear compartment of the endoplasmic 
reticulum-Golgi complex and in the tubes invaginating the nucleus (Coene et a l, 1997). 
Many line of evidence suggests that BRCAl plays an important role during mammary 
epithelial cell proliferation and differentiation. As most of the breast cancer cases are 
associated with loss of BRCAl in humans, it can be thought that this gene provides an 
important growth regulatory function in mammary epithelial cells (Lane et a l, 1995). 
Murine homologue of BRCAl was found to be widely expressed in proliferating and 
differentiating cell types in the mouse during embryonic and mammary gland
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development, and in adult tissues (Marquis et a i, 1995). Identification of the BRCT 
domain, which was found at the carboxyl terminal of BRCAl and was conserved in 
53BP1 (p53 binding protein) and the yeast DNA repair protein RAD9 in 1996, 
elucidated the fact that BRCAl encoded proteins are likely to function in the cell 
nucleus and may be involved at cell-cycle checkpoints and DNA repair (Koonin and 
Altschul, 1996). Although BRCAl was found to be related to the growth regulation of 
mammary epithelial cells, exact function of the gene and the proteins that it interact with 
were not elucidated till the identification of BARD 1 (Wu et al., 1996). Very recently 
BRCAl was shown to be involved in DNA repair. In 1997, Scully et al., found that 
BRCAl was associated with RAD51 in mitotic and meiotic cells, suggesting that 
BRCAl may participate in some nuclear processes such as recombination and DNA 
repair (Scully et al., 1997(a)). Similarly, usage of hydrophobic cluster analysis in 
combination with linear methods of sequence analysis by Callebaut and Momon , led to 
the identification of the presence of the repeated motif in the C-terminus of BRCAl 
named BRCT, among several nuclear proteins closely related to cell-cycle regulation and 
DNA repair (Callebaut and Momon, 1997). Very recently Scully et al., hypothesized 
that BRCAl is a component of RNA polymerase holoenzyme (Scully et al., 1997(b)). 
BRCAl will be discussed in more detail in chapter II.
1-4.2 BRCA2
The breast cancer susceptibility gene BRCA2 was located to chromosome 
13ql2.5 in 1994 (Wooster et al., 1994). By performing genomic linkage analysis to 15 
families that were not linked to BRCAl but had multiple cases of early-onset breast 
cancer, Wooster et al., localized the second breast cancer susceptibility gene roughly to a
6-cM interval on chromosome 13ql2-ql3, between the markers D13S1444 and 
D13S310, close to the marker D13S260. The further localization was done by Schutte et
H
a i, (1995). Afterwards the gene was partially isolated by positional cloning in 1995 
(Wooster et a l, 1995). The complete BRCA2 gene was then cloned in 1996 (Tavtigian 
ei al., 1996). The identified portion of BRCA2 cDNA consists of 11385 basepairs and 
lacks a poly adénylation signal and poly A tail. The BRCA2 gene encodes a 3418 amino 
acid long polypeptide that lacks significant homology to previously described proteins . 
However a very weak similarity to BRCAl protein was observed, that was restricted to 
a 80 amino acid long region (aa. 1394-1474 in BRCAl and aa. 1783-1863 in BRCA2); 
(Wooster et a i, 1995). Transcription of the gene results in a 11-12 kb transcript and 
high expression was detected at testis, breast and thymus with less amounts at spleen, 
lung and ovary. The gene is composed of 27 exons and distributed over roughly 70 kb of 
genomic DNA. The cDNA consists of >60% A/T unlike most of the human proteins. 
There is a CpG rich region at the 5' end of the gene suggesting a regulatory region. 
BRCA2 encoded protein was found to be highly charged, approximately one quarter of 
all amino acids were acidic or basic (Tavtigian et al., 1996). Working with BRCA2 was 
hard because another very important TSG, the retinoblastoma gene, was located very 
close to the BRCA2 locus. In 52-63% of 78 sporadic primary breast tumors, allelic 
imbalance was observed at the 13q loci, 9 of which showed Al at BRCA2 locus but not 
Rb and 6 of which showed Al at Rb locus but not in BRCA2 (Hamann et al., 1996). 
This data suggests that Rb and BRCA2 are distinct targets in sporadic breast cancer and 
the mutation incidence of BRCA2 in sporadic breast cancer is significantly higher than 
BRCAl but still rare.
Germline mutations in the BRCA2 gene are believed to be associated with 
approximately 45% of breast cancer families and carriers have a moderately increased 
risk for developing ovarian cancer (Wooster et al., 1994). As most breast tumors that 
occur in patients with germ-line BRCA2 mutations have been found to have a mutations 
that result in the loss of the wild-type BRCA2 allele, this gene is believed to be tumor 
suppressor (Collins et al., 1995). Analysis of a family with multiple cases of male breast
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cancer but no increase in female breast cancer identified the fact that BRCA2 confers 
high susceptibility to male breast cancer (Thorlacius et al., 1995). As in the case of 
BRCAl most of the mutations observed in BRCA2 result in the formation of truncated 
forms of the protein (Wooster ei al., 1995) (Phelan et al., 1996).
Identification of the second breast cancer susceptibility gene BRCA2, allowed a 
comparison between the two breast cancer susceptibility genes, BRCAl and BRCA2 
(Tavtigian et al., 1996). Both genes are rich in A/T content, contain a huge exon 11 
(3426 bp for BRCAl and 4932 bp for BRCA2) and are distributed over a 70-100 kb 
region in genomic DNA. Translation results in the production of highly charged proteins. 
Most of the mutations result in the formation of truncated forms of the protein products 
in both genes. Expression patterns of BRCAl and BRCA2 are very similar, that it is 
highest in testis and breast.
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CHAPTER II
BRCAl
2-1 LOCALIZATION OF EARLY-ONSET FAMILIAL BREAST CANCER TO 
CHROMOSOME 17q21
The first breast cancer susceptibility gene was identified by linkage analysis (Hall 
et al., 1990). Linkage analysis can reveal the chromosomal location of the genes of 
interest by identifying polymorphic genetic markers of known location that are 
coinherited with the disease in families. These markers were originally protein 
polymorphisms, but have been replaced by DNA markers such as RFLPs (restriction 
fragment length polmorphisms) and VNTRs (variable number- of tandem repeat 
polymorphisms) (Bowcock, 1993). As the family history of the disease was a significant 
risk factor in all populations, breast cancer was found suitable for this approach. 
Mapping the genes for familial breast cancer was important because alterations at the 
same loci may also be responsible for the sporadic cases. The main problems in the 
mapping of these genes were the unavoidable epidemiological realities and the molecular 
heterogeneity of the disease. The disease was common but only a small proportion of the 
disease was attributed to inherited susceptibility. Thus, members of a family may have 
multiple number of cases without inherited susceptibility and sporadic cases may occur 
in families with inherited disease.
Hall et al. made an extensive study of 23 families with 146 cases of breast cancer 
in 1990. These families shared the epidemiological features that were characteristics of
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familial versus sporadic breast cancer: young age of diagnosis, frequent bilateral disease 
and frequent occurrence of disease among men. Genetic analysis of the 329 people in 
those families revealed a lod score of 5.98 for linkage of breast cancer susceptibility in 
early-onset families to D17S74, which is located in a 1 to 2 megabase region on 
chromosome 17q21. Negative lod scores were found in families with late-onset disease 
(Hall etal., 1990). A map of human chromosome 17ql2-23 is given in figure 2-1.
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Figure 2-1: Map of human chromosome 17ql2-23
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Linkage of breast cancer susceptibility gene BRCAl to chromosome 17q21 was 
then confirmed by a number of studies. In 1991 Narod et al. showed that the 
chromosomal region 17ql2-ql3 was associated with hereditary ovarian cancer as well as 
hereditary breast cancer (Narod et a i, 1991). Analysis of a single multi-affected breast- 
ovarian cancer pedigree showed the consistent inheritance of markers on chromosome 
17q with the disease confirming that the disease in this family was due to the BRCAl 
gene ( Kelsell et al., 1993). Involvement of BRCAl in sporadic breast cancer was also 
identified in a study in which 100 cases were analyzed for the LOH by using 10 PCR- 
based polymorphic markers from 17q 12-21. Allele losses were detected in 40 of 100 
tumors informative for at least one of the markers analyzed. The most frequently deleted 
region overlaps with the minimal region containing the BRCAl gene, suggesting that 
this gene might also be associated with the development or progression of a proportion 
of sporadic breast tumors ( Nagai et al., 1994).
In 1994 Neuhausen et al., localized BRCAl to a region of about 600 kilobase 
pairs (kb) between the markers D17S1321 and D17S1325 by constructing a physical 
map of the BRCAl region which extended from the proximal boundary at D17S776 to 
the distal boundary at D17S78 (Neuhausen et al., 1994). Localization of BRCAl to a 
600-kb region was one of the most important steps towards the cloning of the breast and 
ovarian cancer susceptibility gene, BRCAl.
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In October 1994, Miki et ai, identified a strong candidate for 17q-linked 
BRCAl gene by positional cloning methods. For this purpose, first they found out sixty- 
five expressed sequences within the 600-kb region on 17q21. Characterization of these 
expressed sequences by DNA sequence, database comparison, transcript size, expression 
pattern, genomic structure and DNA sequence analysis of individuals from breast cancer 
kindreds identified three expressed sequences that merged into a small transcription unit. 
This transcription unit was located in the center of the 600-kb region.
Combination of sequences obtained from amplified polymerase chain reaction 
(PCR) products, complementary DNA (cDNA) clones and hybrid-selected sequences 
revealed the full-length BRCAl cDNA. Translation of this cDNA showed that it has a 
single, long open reading frame encoding a protein of 1863 amino acids (Miki et a l, 
1994).
In order to prove that BRCAl is responsible for susceptibility to breast and 
ovarian cancer it should be demonstrated that there are mutations in this locus in carrier 
individuals from kindreds that segregate 17q-linked susceptibility to breast and ovarian 
cancer. Analysis of different members from these kindreds have shown that there are 
ffameshifl, nonsense and regulatory mutations that cosegregate with predisposing 
BRCAl alleles suggesting that this gene is BRCAl (Miki et al., 1994). Mutation 
analysis of BRCAl gene of affected kindred members, performed by a number of 
laboratories after the cloning of BRCAl, further proved that this gene was responsible 
for the hereditary form of breast and ovarian cancer. Analysis of 50 probands with a 
family history of breast and/or ovarian cancer by Castilla et a l (1994), 63 breast cancer 
patients by Friedman et a/. (1994), for germline mutations in the coding region of 
BRCAl showed that there were germline mutations in the BRCAl gene in more than 
80% of affected families.
2-2 MOLECULAR CLONING OF BRCAl
2 0
Miki et ah, found out that BRCAl gene is composed of 24 exons 22 of which 
are transcribed into a 7.8 kb transcript and is distributed over roughly 100 kb of genomic 
DNA. The exon structure of BRCAl is schematically represented in figure 2-2. The 
transcript was found to be most abundant in testis, thymus, breast and ovary. Probing 
genomic DNA samples from different species including humans, mice, rats, rabbits, 
sheeps, and pigs with BRCAl sequences revealed the fact that BRCAl is conserved 
among mammals (Miki et ah, 1994).
During the cloning of the gene, cDNA clones lacking one or more exons within 
the 5' portion of the gene were isolated indicating the presence of alternative splicing 
(Miki et ah, 1994). In 1996, Lu et ah identified the splice variants of BRCAl which 
lacked most of the nucleotide sequences from exon 11 and were expressed abundantly in 
tumor-derived and normal breast cell lines (Lu et ah, 1996). These alternative BRCAl 
transcripts were in frame and coding 80-85 kD BRCAl-derived proteins, lacking 
approximately 60% of the internal amino acids of full-length BRCAl. A schematic 
representation of the splice variant of BRCAl are given in figure 2-3.
Generation of different mRNA species can be due to the presence of alternative 
splicing as indicated above, as well as the presence of distinct transcription sites. In 
1995, Xu et ah, identified the presence of two different transcripts generated by the 
alternative use of dual promoters and alternative splicing, in primary tissues including 
that of placenta, mammary gland, testis and thymus, six normal or cancer cell lines, four 
primary breast tumor tissues and four primary ovarian tumor tissues (Xu et ah, 1995). 
In all of the samples studied, both transcripts were detected. The transcript named 
exon la (which starts from the 5' l^t transcription start site was expressed abundantly in
2-3 DNA, RNA AND PROTEIN STRUCTURE OF BRCAl
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Figure 2-2: The exon structure of BRCAl
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Figure 2-3: Splice variants of BRCAl
(1; full-length BRCAl; 2: BRCAl lacking exons 9 and 10; 3; BRCAl splice variant 
lacking 3309 nucleotides from exon 11; 4; BRCAl splice variant lacking exons 9 and 10 
as well as 3309 nucleotides from exon 11)
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Figure 2-4: Exon la and exon lb transcripts of BRCAl
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mammary gland, and the transcript named exon lb (which starts from the 5' 
transcription start site) was expressed abundantly in placenta, indicating a tissue-specific 
expression pattern. Transcription of a single gene from multiple promoters may provide 
additional flexibility in the control of gene expression (Kozak., 1991). A schematic 
representation of exon la and exon lb transcripts of BRCAl are given in figure 2-4.
Sequence analysis of human BRCAl revealed the presence of a RING finger 
domain, two basic motifs (NLS), a granin sequence, a leucine zipper motif, and a highly 
conserved carboxyl terminal harboring the BRCT motif (Table 2-1).
Table 2-1: A summary of the identified domains and motifs on BRCAl
NAME OF THE MOT№ LOCATION 
(aa, residues)
REFERENCE
RING finger motif 24-64 M ikie/a/., 1994
Nuclear Localization Signal 500-506 and 604-611 Lane et al., 1995
Granin motif 1214-1223 Jensen et al., 1996
Leucine zipper motif 1209-1230 Lane et al., 1995
Carboxyl terminal 
acidic loop
carboxyl terminal Miki et al., 1994
Carboxyl terminal minimal 
transactivation domain
1760-1863 Monteiro et al., 1996
Carboxyl terminal 
BRCT motif
1671-1796 \lo\i et al., 1996
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Smith-Waterman and BLAST searches identified that the BRCAl-encoded 
protein contains the consensus Cysj-His-Cys4 (C3HC4) zinc-finger (ring finger) motif 
near the amino-terminus (amino acids 22-64) indicating the presence of a zinc-finger 
domain which suggests that BRCAl might have a possible role in transcriptional 
regulation (Miki et al., 1994). A schematic representation of the BRCAl zinc finger 
domain is illustrated in figure 2-5 (Bienstock et al., 1996). In 1996, Wu ei al., identified 
a novel protein, by using yeast two-hybrid system, named BRCAl-associated ring 
domain (BARDl), that was interacting with the N-terminal region (minimal region aa.s 
1-100) of BRCAl in vivo. The gene coding for BARDl was shown to be located on 
chromosome 2q and just like BRCAl contains a N-terminal ring motif and a C-terminal 
BRCT domain. These two proteins were shown to be co-expressed in the tested breast 
and ovarian carcinoma cell lines. It was also shown that BARDl-BRCAl interactions 
were disrupted by tumorigenic amino acid substitutions in BRCAl indicating that the 
formation of this complex was important for the BRCAl-mediated tumor suppression. 
Wu et al., concluded that mutations in the BARDl may also play an important role in 
breast carcinogenesis.
Smith-Waterman and BLAST searches also identified an acidic blob in the 
carboxyl region of the gene indicating a transactivation function. Examination of the 
globular domains of BRCAl in order to define the sequence similarities, revealed a 
similarity between the 202 amino acid residue long C-terminal globular domain of 
BRCAl and a human protein named p53BPl. Computer analysis showed that the same 
conserved region was also present in the yeast RAD9 protein, which is involved in the 
control of the DNA damage induced cell-cycle arrest. This domain was named as BRCT 
(BRCAl C-terminus) and proposed to confer the ability to suppress breast cancer cell 
growth to BRCAl (Koonin and Altschul, 1996) as the BRCAl mutants lacking this 
region were incapable of performing their tumor suppressor functions (Holt et al., 
1996).
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Another domain identified on the BRCAl protein is the granin domain which is 
located at a close proximity of the N-terminal (amino acids 1214-1223) (Jensen et a i, 
1996). By using SWISS PROT database, Jensen et ai, searched for protein motifs in 
BRCAl. Some biochemical features as well as the conserved granin sequence indicated 
that BRCAl can be a granin. These features include the similarity between the isoelectric 
points (granins; between 4.9-5.6; BRCAl; 5.2) and the acidic amino acid composition of 
both BRCAl and the granins.
Immunoprécipitation analysis of BRCAl by anti-BRCAl antibodies in 
synchronized T24 bladder carcinoma cells, identified the presence of two forms of 220 
kD BRCAl protein one hypo-phosphorylated and the other hyper-phosphorylated (Chen 
et a l, 1996). The phosphorylation status of specific domains of various proteins often 
correlates with many respects of cell growth and transformation. In this study it was also 
shown that phosphorylation of BRCAl was cell cycle dependent, becoming evident in 
mid/late Gl, rising to maximum in S phase and remain elevated through M phase. In 
order to define whether the phosphorylation of BRCAl was carrfed out by cell-cycle 
dependent protein-kinases, cell lysates were immunoprecipitated with antibodies against 
various cyclin dependent kinases (cdk) and cyclins. Reimmunoprecipitation of the 
precipitates with anti-BRCAl antibodies indicated that BRCA2 was phosphorylated by 
cdk-2 and kinases associated with cyclins D and A, consistent with the initiation of 
phosphorylation in mid-Gl and maximum phosphorylation during S phase.
Identity of the phosphorylated amino acid was assessed by immunoprecipitating 
BRCAl with antibodies against the protein, and then performing a phosphoamino acid 
analysis (Ruffher and Verma, 1997). It was found out that, it was a serine 
phosphoprotein that undergoes hyperphosphorylation during late Gl and S phases of the 
cell cycle and was transiently dephosphorylated after M phase.
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Figure 2-5: RING (zinc) finger domain of BRCAl
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2-4 CELLULAR LOCALIZATION OF BRCAl ENCODED PROTEINS
The localization of a protein may indicate some clues about its functions in a cell, 
therefore subcellular localization of the BRCAl protein was extensively studied.
In 1995 Chen et al., found out that BRCAl is a 220 kD protein and is localized 
in the nucleus of normal cells but the protein was aberrantly excluded from the nucleus 
and located in the cytoplasm in breast and ovarian cancer cell lines, by using polyclonal 
antibodies against the BRCAl protein (Chen et a/., 1995). In contrast to these findings, 
Scully et al., found out that BRCAl was exclusively nuclear regardless of cell type. 
Usage of polyclonal and monoclonal antibodies against the BRCAl protein revealed 
that, BRCAl was located in the nucleus of both normal cells and cancer cells including, 
primary human diploid fibroblasts, primary human mammary epithelial cells and all the 
tested breast and ovarian cancer cell lines (Scully et al., 1996). Both groups agreed that 
the protein was nuclear in normal cells but there was still a confusion about the exact 
localization of the BRCAl encoded protein.
Another conflicting data was found out by Jensen et al. (1996), who proposed 
that BRCAl was a 190 kD secreted protein, belonging to the granin family. 
Immunoblotting and confocal imaging of normal human mammary epithelial cells and the 
breast cancer cell lines with antibodies against the BRCAl protein showed that BRCAl 
was localized to the Golgi network and secretory vesicles (Jensen et al., 1996). But no 
other study except this provided evidence that BRCAl is a 190 kD secreted protein. 
Later on, it was shown that the antibodies used by Jensen et al. were cross-reacting with 
the epithelial growth factor receptor (EGFR) which was a 190 kD protein and had a 
high expression pattern in the MDA-MB-468 cells used in the study (Wilson et al., 
1996).
In 1996, Chen et al., characterized the BRCAl as a 220 kD nuclear 
phosphoprotein by using highly specific antibodies. Generation of a baculovirus-based
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expression system, allowed the purification of large amounts of full-length BRCAl. Co­
migration of this in-vitro translated, recombinant, baculovirus derived BRCAl with 
BRCAl from human breast epithelial cell line, indicated that BRCAl is a 220 kD 
protein. Immunostaining of bladder carcinoma cells with the two highly specific 
antibodies indicated the nuclear localization of the BRCAl protein.
A study concerning the functional significance and cellular localization of 
BRCAl splice variants showed that the alternatively spliced form of BRCAl (BRCAl A 
672-4095) which was lacking a large portion of exon 11 was located in the cytoplasm, in 
contrast to the full-length BRCAl (Thakur et al., 1997). This was explained by the 
presence of two nuclear localization signals (NLS) in exon 11 (amino acids; 500-508 and 
609-615). The localization of the BRCAl splice variant lacking exon 11 (BRCAl A1 lb) 
had also been shown to be cytoplasmic in another study, again pointing out the presence 
of NLSs in exon 11, which mediate the translocation of BRCAl from cytoplasm to the 
nucleus (Wilson et al., 1997). In this study it was also shown that overexpression of 
BRCAl but not BRCAlAl lb was toxic to the cells, indicating the accumulation of full 
length BRCAl in the cytoplasm and the nucleus.
Very recently BRCAl is localized in the perinuclear compartment of the 
endoplasmic reticulum-Golgi complex and in tubes invaginating the nucleus. Coene et 
al., (1997) produced polyclonal antibodies against exon 11 and the C-terminal region of 
BRCAl and then used these antibodies and two other monoclonal antibodies to stain 
human breast cancer cells, human T-leukemia cells known to express BRCAl, 
fibroblasts, normal breast epithelium and carcinoma cells. Confocal analysis indicated the 
presence of BRCAl in the cytoplasm especially within the perinuclear region and as dot­
like structures in the nucleus. Further confocal analysis showed that the dot-like 
structures in the nucleus in fact represent cross-sections through perinuclear originated 
threads or tubes and that number of these channels were increased in malignant cells 
compared to normal cells. Co-localization of these tubes with endoplasmic reticulum-
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Golgi complex specific proteins indicated that these nuclear tubes may have been 
originated from the cytoplasmic structures. This study also indicated that the nuclear 
detection of BRCAl was fixation dependent, that the cell-fixation procedures influence 
the outcome of the experiments. Therefore the previously described different subcellular 
localizations of BRCAl may be due to the fixation techniques. Similarly, identification 
of different molecular weights for the BRCAl may be due to the cross-reactivity of the 
antibodies used in the studies.
2-5 PUTATIVE FUNCTIONS OF BRCAl 
2-5.1 BRCAl IS A TUMOR SUPRESSOR GENE
Most of the tumors that occur in patients with germline BRCAl mutations 
display heterozygosity at this locus which involves loss of the wild-type BRCAl allele 
indicating that BRCAl can be tumor suppressor acting as a negative regulator of tumor 
growth (Smith et ah, 1992). Cancer predisposing alleles typically carry mutations that 
result in loss or reduction of the gene function. A single inherited copy of the mutant 
allele results in predisposition to cancer and a mutation which results in the loss or 
inactivation of the gene in the wild-type allele completes one of the steps towards 
carcinogenesis (Miki et ah, 1994). The predisposing allele generally behaves as a 
recessive allele in somatic cells but the predisposition to cancer is inherited as a 
dominant genetic trait. In breast cancer patients who carry BRCAl predisposing alleles, 
observations have shown that malignancy results from the loss of the wild-type allele 
suggesting that BRCAl is a tumor suppressor (Kelsell et ah, 1993) (Neuhausen and 
Marshall, 1994). This hypothesis was supported by the identification of the fact that 
BRCAl negatively regulates the proliferation of mammary epithelial cells (Thompson et
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a i, 1995), transfection of MCF-7 breast cancer cell lines with wild-type BRCAl inhibits 
tumor progression (Holt et al., 1996) and antisense RNA against BRCAl transforms 
fibroblasts (Rao et al., 1996).
Thompson et al. compared the expression of BRCAl in normal mammary 
epithelium, carcinoma in situ and invasive breast cancer by the use of antisense 
oligonucleotides against BRCAl. Although the inhibition of BRCAl expression by these 
oligonucleotides did not affect the non-mammary epithelial cells, accelerated growth of 
mammary epithelial cells was observed, suggesting the role of BRCAl to be a negative 
regulator of mammary epithelial cell growth. Their results also indicated that BRCAl 
mRNA expression was five-to-ten fold higher in normal mammary tissue than in invasive 
breast cancer samples and that BRCAl mRNA levels were decreased during transition 
from carcinoma in-situ carcinoma to invasive cancer. Thus, BRCAl is expressed at 
lower levels in breast cancer cells than in normal mammary cells and diminished 
expression of BRCAl increases the proliferation rate of breast epithelial cells 
(Thompson et al., 1995).
Analysis of the tumor inhibition effects of BRCAl on breast cancer cell line 
MCF-7, showed that wild-type BRCAl (but not mutant BRCAl) inhibits growth of 
breast cancer cells in vitro and rescues the cells from the tumorigenic phenotype (Holt et 
al., 1996). MCF-7 breast cancer cell line has very low expression of BRCAl mRNA and 
BRCAl protein and contains a genomic loss of one copy of the 2 Mb region containing 
BRCAl. Transfection of wild-type BRCAl into the breast and ovarian cancer cell lines 
resulted in the inhibition of growth whereas growth inhibition was not observed in 
transfected colon and lung cancer cell lines. This indicates the tissue specificity of 
BRCAl protein in exerting its growth inhibitory effects. Transfection of a mutant 
BRCAl which encodes a 340 amino-acid truncated form did not inhibit the growth of 
the cell lines. Interestingly, a truncated 1835 amino-acid long BRCAl protein did not 
inhibit the growth of breast cell lines, while inhibiting the growth of ovarian cell lines.
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This suggests that growth inhibition of breast cancer cells and ovarian cancer cells are 
mediated by different mechanisms and that this difference depends on the length of the 
truncated protein. Similarly when MCF-7 cells that were transduced with wild-type 
BRCAl were injected in nude mice, no tumor development was observed, but when 
MCF-7 cells lacking wild-type BRCAl were injected in nude mice, tumors developed in 
five of six mice indicating that BRCAl can inhibit mouse breast carcinogenesis. Holt et 
al., also demonstrated that wild-type BRCAl can inhibit the growth of already 
established breast tumors in nude mice and improved the survival of these animals (Holt 
e ta l, 1996).
Rao et al. (1996), postulated that if BRCAl functions as a growth regulator in 
normal cells, inhibiting its function should result in transformation. Transfection of 
NIH3T3 cells that were expressing significant levels of BRCAl, with vectors containing 
antisense BRCAl cDNA resulted in 3-5 fold decrease in the expression of BRCAl. 
There were no significant morphological changes in these cells, but increased 
proliferation rate, anchorage independence and the ability to grow in serum-free or low 
serum culture medium were observed which are the three important characteristics of 
transformed cells. Testing the tumorigenicity of the BRCAl-antisense cDNA harboring 
cells in vivo, showed that these cells were capable of generating tumors in nude mice.
All these data support the hypothesis that BRCAl is a potent tumor suppressor 
gene and that the functional BRCAl protein is present in normal breast and ovarian 
epithelium tissue and is altered, reduced, or absent in some breast and ovarian tumors 
(Miki e ta l,  1994)
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2-5.2 BRCAl, A SECRETED PROTEIN?
Identification of a granin consensus at BRCAl amino acids 1214-1223, 
implicated the possibility that BRCAl can be a secreted protein (Jensen et al., 1996). 
Granins are secreted proteins, hence they are located in secretory granules. The 
expression of some granin family proteins is regulated by estrogen and their secretion is 
triggered by cyclic AMP (Thompson ei al., 1992). Granins contain a characteristic ten 
amino acid long motif and their overall amino acid content is highly acidic (Huttner et 
a/., 1991). Intracellularly, granins are involved in regulated secretoiy pathway, and 
extracellularly they serve to regulate cellular secretion of other peptides in an endocrine 
or paracrine fashion.
As indicated in section 2-4, none of the other studies indicate that BRCAl may 
function as a secreted protein. Rather, they indicated the exact localization of BRCAl to 
the nucleus. Therefore now, it is unlikely that BRCAl is a secreted protein.
2-5.3 BRCAl AS A REGULATOR OF TRANSCRIPTION
The first identified conserved domain on BRCAl was the ring finger domain near 
the amino-terminus (amino acids 22-64). The members of the RING finger family are 
putative DNA binding proteins, some of which are implicated in transcriptional 
regulation (Miki et al., 1994). Similarly, presence of a highly negatively charged 
carboxyl terminal may indicate a transcriptional regulation function as in many 
eukaryotic transcription activators such a region is found (Monteiro et al., 1996). Also 
the presence of the two nuclear localization signals in exon 11 and identification of the 
subcellular localization of BRCAl to be nuclear supplied further evidence that BRCAl 
acts as a regulator of transcription (Coene et al., 1997). BRCAl was also shown to 
induce apoptosis when overexpressed in several normal or malignant cell lines indicating
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that BRCAl products may act as a transcriptional regulator to activate or inhibit 
apoptosis inducing or repressing genes, respectively (Shao ei a l, 1996).
The most convincing data supporting the transcriptional regulator role of 
BRCAl was found out by Monteiro et al., 1996. It was found out that, the C-terminal 
of the BRCAl protein, comprising exons 16-24 (aa: 1560-1863) can act as a 
transactivation domain when fused to GAL4 DNA binding domain in both yeast and 
mammalian cells. Also the minimal transactivation domain was found to be involved by 
exons 21 to 24 (aa 1760-1863). Their results also indicated that mutations in the C- 
terminal region found in patients with breast or ovarian cancer had markedly impaired 
transcription activity.
Co-purification of the wild-type BRCAl with the mammalian RNA polymerase 
II holoenzyme by Scully et al., suggested that BRCAl was a component of RNA 
polymerase II holoenzyme, and therefore involved in the regulation of transcription of at 
least some genes (Scully et al., 1997). Purification of the holoenzyme from the HeLa 
whole cell extract, recovered the holoenzyme, and the components of the holoenzyme 
were separated by density gradient centrifugation. Results indicated the presence of 
BRCAl in RNA polymerase II holoenzyme in association with pol II (core unit) and 
cdk8 (mammalian counterpart of the yeast SRBIO). Similarly, BRCAl was 
coimmunoprecipitated with the basal transcription factors TFIIF, TFIIE, and TFIIH. The 
effects of BRCAl mutations that generate truncated protein products, on holoenzyme 
binding was also assessed. Results indicated that the truncated product was also able to 
bind holoenzyme but with a decreased efficiency, indicating the importance of the C- 
terminal of BRCAl in this functional complex. Previously, it had been shown that 
hRADSl, which is shown to be associated with BRCAl in mitotic and meiotic cells 
(Scully et a l, 1997), was also a component of the RNA polymerase II holoenzyme 
(Maldonato et a l, 1996). The inability to purify hRADSl with BRCAl in this study was
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explained by the cell-cycle dependent association of the two proteins and the cells used 
in this study were asynchronous.
2-5.4 ROLE OF BRCAl IN APOPTOSIS
In a wide variety of human malignancies decreased ability to undergo apoptosis is 
observed. In breast and ovarian carcinomas, this could be due to lack/decreased levels of 
functional BRCAl proteins. In 1996, it was shown that BRCAl plays a critical role in 
the regulation of programmed cell death, such that overexpression of BRCAl results in 
apoptosis (Shao et al., 1996). In order to define the role of BRCAl in apoptosis, Shao et 
al., developed mouse fibroblast cell lines and human breast cancer cell lines expressing 
BRCAl by transfecting NIH3T3 and MCF7 cells with a vector harboring the BRCAl 
cDNA. The morphological differences between the BRCAl transfectants and the 
parental NIH3T3/MCF7 cells in prolonged periods of cell culture indicated that 
constitutive high level expression of BRCAl may result in apoptosis. Serum withdrawal 
is known to induce apoptosis and by comparing the effects of serum deprivation on 
induction of apoptosis in BRCAl transfectants and the parental cells, Shao et al., 
showed that BRCAl transfectants were more prone to apoptosis. Their results also 
indicated that exon 11 of BRCAl was dispensable for the apoptotic function as the 
BRCAl cDNA they used lacked the majority of exon 11. The mechanisms underlying the 
induction of apoptosis by BRCAl are not clear but it is suggested that BRCAl products 
may activate death inducing genes or repress death inhibiting genes either by direct 
protein-protein interactions or by acting as a transcriptional regulator.
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Very recently it was shown that BRCAl and hRADSl colocalize in S phase, 
interact physically and share a common space on the surfaces of zygotene and pachytene 
meiotic chromosomes, suggesting that BRCAl participates in nuclear processes 
including recombination and genome integrity control (Scully el al., 1997).
Usage of several different monoclonal and polyclonal antibodies indicated that 
endogenous BRCAl forms discrete, dot-like structures in the nucleus in a S-phase of the 
cell-cycle dependent manner (Scully et al., 1996). hRadSl is the human homologue of 
RecA and is a member of protein family which functions as a mediator of DNA strand- 
exchange functions, leading to recombination (Baumann et al., 1996). Mutations in the 
RAD51 gene result in early embryonic lethality in mice (Tsuzuki et al., 1996), and 
meiotic recombination and double-strand break-repair abnormalities in yeast (Shinohara 
et al., 1992). Just like BRCAl, RAD51 forms S phase-specific nuclear dots (Tashiro et 
al., 1996). This similar timing of appearance of nuclear dots suggests the colocalization 
of the protein products of these two genes in the same structure. Immunostaining of 
MCF7 cells with antibodies against BRCAl and hRADSl showed that these two 
proteins were colocalized in nuclear dot patterns (Scully et al., 1996). Further analysis 
of this interaction revealed that this colocalization was mediated by sequences encoded 
by the 11*^  exon of BRCAl.
Presence of such an interaction in mitosis and the background knowledge about 
the presence of RadSl on unique, meiosis-specific DNA-protein complexes named 
synaptonemal complexes (Terasawa e/a/., 1995), (Bishop, 1994), raised the probability 
that these two proteins may interact during meiosis. Analysis of the nuclei of zygotene 
spermatocytes obtained from human testis showed that both proteins were present on 
asynapsed elements of synaptonemal complexes.
2-5.5 BRCAl AND DNA REPAIR
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Probable involvement of BRCAl in DNA repair was also assessed by Callebaut 
et al., (1997). Identification of the presence of the approximately 95 amino acid (aa) 
long repeated motif in the C-terminus of BRCAl named BRCT (Koonin and Altschul, 
1996), among several nuclear proteins closely related to cell-cycle regulation and DNA 
repair, including the 53BP1 (p53 binding protein 1), RAD9, XRCCl, RAD4, suggested 
that BRCAl was involved in DNA repair (Callebaut et al., 1997). Positions of the 
BRCT domains in BRCAl, 53BP1, RAD9, XRCCl, RAD4 are shown in figure 2-6.
The BRCT domain is predicted to consist of four P-strands and two a-helices, 
with the P-strands probably forming a core sheet structure. The size of the domain, its 
predicted secondaiy structure and the observed pattern of amino acid conservation 
indicate that this domain may be involved in protein-protein interactions. All proteins 
that contain the BRCT domain, the BRCT superfamily, are large multi-domain protein 
that are associated with DNA damage-responsive cell cycle checkpoints.
A model indicating the interaction of BRCAl, BRCA2 and p53 has just been 
proposed (Figure 2-7), (Brugarolas and Jacks, 1997). Very recently it was shown that, 
p21 and MDM2 levels were increased in Brcal deficient mice, indicating a linkage 
between the cell cycle control and Brcal (Hakem et al., 1996). According to this model, 
RAD51, BRCAl and BRCA2 form a complex and repair the damaged DNA. But when 
a mutation occurs in either BRCAl or BRCA2, and repair is failed, p53 is activated.
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Figure 2-6 Positions of the BRCT douiains in BRCAl, 53BP1, RAD9, XRCCl, 
RAD4 (blue boxes indicate the BRCT modules)
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Figure 2-7: Interaction of BRCAl, BRCA2 and p53 in response to DNA damage
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Germline mutations of the BRCAl tumor suppressor gene are involved in a 
significant fraction of hereditary breast and ovarian cancers. So far, more than 100 
distinct mutations have been identified in breast or breast/ovarian cancer families. Of 
these, a founder effect, 185delAG, has been observed in Ashkenazi Jewish families (Offit 
et al., 1996). Allelic deletions that include the BRCAl locus are common in breast and 
ovarian cancers, implying that somatic mutations of this gene may play an important role 
in the more common sporadic forms of these tumors as well (Takahashi et al., 1995). 
Somatic point mutations in BRCAl in sporadic tumors are very rare (Futreal et al., 
1994), but complete somatic deletion of one allele of BRCAl occurs approximately 50% 
of sporadic breast cancers and 70% of sporadic ovarian cancers (Takahashi et al., 1995). 
Expression analysis of BRCAl mRNA in sporadic breast cancers indicated a decreased 
expression, suggesting that BRCAl is altered at genomic level in hereditary breast and 
ovarian cancer, but at either the genomic or transcriptional levels in sporadic cancer 
(Thompson et al., 1995). Approximately 85% of mutations that have been identified 
throughout the coding region of BRCAl give rise to truncated forms of protein that 
vary in length from 5% to 99% of full-length protein (Shattuck-Eidens et al., 1995). 
This suggests that C-terminal of BRCAl is essential for the normal function of the 
protein in breast epithelial cells. Patients inheriting 1853 Stop were shown to develop 
breast cancer at a very early age (Friedman et al., 1994). Also truncated form of breast 
cancer was shown to be incapable of inhibiting cell growth in vitro (Holt et al., 1995).
Recently, the severity of breast cancers classified according to the proliferative 
index were compared with the positions of mutations in BRCAl, in order to define a 
genotype-phenotype correlation. A significant correlation was found between truncations 
at the N and C termini of BRCAl and the most highly proliferating cancers (Sobol et al., 
1996). Sobol et al., compared two subgroups of BRCAl-associated breast cancer
2-6 MAIN TYPES OF BRCAl MUTATIONS IN BREAST CANCER
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families, the first with highly proliferating tumors, and the second composed of cases 
with a low proliferation rate, in order to define the relation between the proliferation rate 
of B RCA1-associated breast cancers and the site of the germ line mutation in the 
BRCAl gene. Results showed that when the mutation was at the two terminal conserved 
domains of the BRCAl protein, i.e., in the amino and carboxyl termini, the tumors 
showed a more aggressive pattern of proliferation. Similarly, analysis of BRCAl 
mutations have suggested that the risk of breast and ovarian cancer are related to the 
position of the mutation, such that truncating mutations in the first two thirds of the 
coding region were found to be more associated with a higher ovarian cancer risk 
relative to breast cancer risk, than mutations in the last third.
A summary of the identified mutations of BRCAl are summarized in figure 2-8.
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Figure 2-8: The identified mutations of BRCAl
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Mutations of the BRCAl gene were also shown to predispose to colon and 
prostate cancer as well as breast and ovary cancer. In 1994, Ford et al., studied 33 
families for linkage to BRCAl, in order to establish whether gene carriers were at an 
increased risk of any cancer other than breast and ovarian cancer. 87 cancers other than 
breast or ovarian cancer were observed in individuals with breast or ovarian cancer and 
their first-degree relatives compared with 69.3 expected, based on national incidence 
rates. Significant excesses were observed for colon cancer (P=0.002) and prostate cancer 
(P=0.006). No significant excesses were noted for cancers of other tissues.
2-7 EXPRESSION OF BRCAl IN DIFFERENT STAGES OF DEVELOPMENT
Changes in the normal pathways of differentiation and development is one of the 
causes of carcinogenesis (Rajan et a l, 1997). The relationship between carcinogenesis 
and development is well exemplified in breast, that the hormonal changes taking place 
during menarche, menopause and age of the first full-time pregnancy are important 
factors by means of the occurrence of breast cancer. Thus, mammary gland development 
and mammary gland carcinogenesis are basically related (Rajan et al., 1997). Because 
most of the breast cancer cases are associated with loss of BRCAl in humans, it can be 
thought that this gene provides an important growth regulatory function in mammary 
epithelial cells (Lane et al., 1995). Several line of evidence suggest that BRCAl plays an 
important role in the regulation of mammary epithelial cell growth. Murine homologue 
of BRCAl was found to be widely expressed in proliferating and differentiating cell 
types in the mouse during embryonic and mammary gland development, and in adult 
tissues (Marquis et a l, 1995). Understanding the role of hormones in the regulation of 
BRCAl expression in breast and the role of BRCAl in mammary gland development 
and differentiation is important because elucidation of these facts would lead to the 
identification of the relationship between carcinogenesis and the presence of mutant
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BRCAl. For this reason, Marquis et al. analyzed the temporal and spatial pattern of 
Brcal expression during normal mouse embryogenesis, in adult tissues, in the mammary 
gland during postnatal development, and in the mammary glands of animals whose levels 
of ovarian hormones have been experimentally manipulated. The embryonic expression 
observations indicated that Brcal was expressed all over the embryo in the very 
beginning but a change occur in the expression pattern from this diffused pattern to 
tissue-specific pattern during later stages of the development. And these tissues were the 
ones in which rapidly growing cells were undergoing differentiation. Thus it was shown 
that Brcal was expressed in rapidly proliferating cell types which are involved in 
differentiation. The same pattern was also observed during puberty and pregnancy. In 
the beginning of puberty Brcal mRNA levels were found to be considerably higher in 
the differentiating mammary cells compared with males and the expression levels prior to 
puberty. In the same manner mammary epithelial cells proliferate rapidly and undergo 
differentiation during pregnancy. And Brcal mRNA levels show a sharp increase early in 
pregnancy. In the same study tissue distribution of Brcal was also analyzed in adult 
mice, and it was shown that Brcal expression was high in breast (predominantly 
epithelial-specific), ovary (follicular-specific), uterus, testis, thymus, spleen, lymph 
nodes, and the liver. Spatial and temporal expression analysis of Brcal during postnatal 
development of the mammary gland showed that Brcal was expressed predominantly in 
an epithelial-specific pattern in the mammary gland of males and females at all stages of 
postnatal development. These results and the Brcal expression analysis during puberty 
and pregnancy in adult rodents indicated that Brcal plays an important role during 
development and that expression levels of the gene was modified directly or indirectly by 
hormones (Marquis et al., 1995).
Another study concerning the Brcal expression-cell proliferation/differentiation 
relationship was carried out by Lane et al., (1995). In order to define the growth 
regulatory function of BRCAl Lane et al., studied the role of loss of expression of
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BRCAl in the development of breast cancer. Because mouse Brcal shares 58% amino- 
acid identity with human BRCAl, and conserved sequence is an indicator of conserved 
function, and because identification of the role of mouse Brcal in different stages of 
development would provide considerable insight into functional domains of BRCAl, as 
well as the role of human BRCAl in development and carcinogenesis, mice were used as 
an animal model (Lane ei al., 1995). Expression of Brcal in embryonic tissues was 
analyzed by in situ hybridization and revealed the fact that Brcal mRNA expression was 
high in ectoderm derived tissues including brain, skin, and mammary epithelial cells as 
well as in mesoderm derived tissues such as kidney epithelial cells. Expression analysis 
of Brcal in mammary tissue at different stages of maturation supported the results of 
Marquis et al., that Brcal mRNA expression levels increase dramatically during 
pregnancy when mammary epithelial cells start to proliferate and differentiate. Taken 
together, all these results support the model in which Brcal functions as a regulator of 
differentiation (Lane ei a/., 1995).
This hypothesis was further supported by the findings that homozygous 
mutations in Brcal result in early embryonic lethality in mice (Gowen et al., 1996). By 
creating a mouse line carrying a mutation in one Brcal allele (Brcal +/- line), Gowen et 
al., examined the role of BRCAl in normal tissue growth and differentiation and 
generated a potential model for cancer susceptibility associated with loss of BRCAl 
function. Mice that were homozygous for the mutant allele (Brcal -/-) died in utero 
between 10 and 13 days of gestation indicating that Brcal is critical for normal 
development. Abnormalities in these mice were most evident in neural tube that their 
neuroepithelium was highly disorganized, with signs of both rapid proliferation and 
excessive cell death (Gowen et al., 1996).
Necessity of the presence of wild type Brcal in embryonic cellular proliferation 
was also analyzed by Hakem et al. (1996), by generating a null mutation of the Brcal 
gene through deleting exons 5 and 6 (Brcal’■*). The findings of this study indicated that
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mice that were heterozygous for the mutant Brcal (Brcal+/“) were viable, 
phenotypically normal and fertile and did not develop breast and ovarian cancer by 
eleven months of age. However mice lacking a wild type allele of Brcal (Brcal "^ ■) were 
not viable and died early in embryogenesis (before day 7.5 of gestation) indicating that 
Brcal is essential for postimplantation development at the time of initiation of 
gastrulation. In vivo, a dramatic increase in the expression of cyclin-dependent kinase 
inhibitor p21 due to increased p53, and decreased expression of cyclin E and MDM2, 
leading to reduced cell proliferation was observed in these embryos. Hakem et al. 
concluded that the death ofBrcal(5-6) mutant embryos prior to gastrulation may be due 
to a failure of the proliferative burst required for the development of the different germ 
layers.
The increased expression of p21, which encodes a G1 cell cycle inhibitor and is a 
target for p53 transcriptional activation in the Brcal mutants (BRCAl 5·^ ), suggested 
that the failure of the proliferative burst could be due to a G1 cell-cycle arrest, caused by 
increased p21 levels (Hakem et al., 1997). Generation of a BrcaP-^-/-, p53"/' mice and 
BrcaP·^"/·, p21·/· showed that these mutations prolonged the survival of Brcal mutant 
embryos from E7.5 to E9.5. This partial rescue indicates the presence of other genes, 
that take part in the developmental stages that act in association with the BRCAl 
protein.
This relationship of BRCAl, with p53, mdm2, and p21 indicates that BRCAl is 
directly or indirectly linked to cell-cycle.
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Observations indicating the increased expression of BRCAl during rapid cell 
proliferation and/or differentiation (Lane et al., 1995); (Marquis el al., 1995) and the 
presence of dot-like BRCAl structures in the nucleus during S-phase (Coene et al., 
1997), suggested that BRCAl expression levels were modified in relation with the cell 
cycle.
Analysis of BRCAl expression levels in synchronized T24 bladder carcinoma 
cells, revealed that BRCAl expression was very low in early Gl, and increased as the 
cell cycle progress toward late Gl, reached the maximum as the cells enter S phase and 
stayed at the maximum level throughout the S and the M phases (Chen et al., 1996). 
The results of the immunostainings were consistent with the previous results, that when 
synchronized T24 cells were fixed at different stages of the cell cycle and stained with 
antibodies against the BRCAl protein, maximum staining was obtained in the S-phase 
cells.
In contrast to all these data, Aprelikova et a/.(1996), suggested that BRCAl may 
not be directly involved in the regulation of the cell cycle in the breast cancer cells, based 
on the observations that the expression pattern of BRCAl was not changed, when the 
breast cancer cell line MCFIOA cells were arrested by growth factor deprivation or 
stimulation of cell proliferation by re-addition of growth factors.
2-8 EXPRESSION LEVELS OF BRCAl DURING CELL CYCLE
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It had been reported that in addition to genetic factors, hormones of the pituitary 
and ovarian origin, including estrogens, progestins and prolactin, play a role in the 
control of normal and breast tumor cell proliferation (Nandi el al., 1995). It had also 
been reported that, as cells progress from normal to tumorigenic state, response to the 
growth factors was lost (Clarke et al., 1992).
In 1995, Marquis ei al., suggested that the expression pattern of Brea 1 can be 
modulated by ovarian hormones, as the Brcal mRNA levels were shown to be increased 
and stayed elevated throughout the pregnancy in mice. Treatment of ovariectomized 
mice with 17P-estradiol alone, progesterone alone, and with the combination of both 
hormones, showed that when these animals were treated with only any one of the 
hormones, there was no observable increase or only a slight increase in the levels of 
Brcal mRNA expression, respectively, compared to intact mice. And when these animal 
were treated with the combination of the two hormones, there was a 4-to 5-fold increase 
in the expression level. These results suggest that, hormones play a key role in the 
regulation ofBRCAl expression.
Regulation ofBRCAl expression via hormones was also tested in vitro, by using 
estrogen-receptor positive MCF-7 cells (Gudas et al., 1995). Gudas et al., demonstrated 
that the depletion of estrogens resulted in a decreased expression of BRCAl and 
treatment of the these cells with P-estradiol following the depletion, resulted in an 
increased BRCAl expression. As it had been shown that BRCAl transcription was 
regulated with the cell cycle, reaching to maximum levels in S phase (Chen et al., 1996), 
Marks et a/. (1997), investigated whether BRCAl was directly induced by estrogen or 
the increased expression was due to the mitogenic activity of P-estradiol.
By using three estrogen receptor positive (ER·*·) and one estrogen receptor 
negative (ER‘) cell lines, it was shown that following the depletion of estrogen.
2-9 HORMONAL REGULATION OF BRCAl EXPRESSION
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treatment of the ER··· cells resulted in induction of BRCAl, whereas there was no 
change in the expression pattern of BRCAl in ER" cells as expected. Usage of an 
antagonist of P-estradiol, tamoxifen citrate, in MCF7 cells showed that, although the 
expression of pS2 was not induced, BRCAl expression was induced indicating that 
BRCAl expression was not directly affected by P-estradiol. Furthermore, when P- 
estradiol was added to a previously depleted medium, an increase in the number of cells 
undergoing S phase was observed. Similarly use of two other mitogens, epidermal 
growth factor (EOF) and insulin-like growth factor 1 (IGF-1), instead of P-estradiol 
induced the expression of BRCAl in MCF7 cells. Their results indicated that, BRCAl 
expression was linked to a promotion of DNA synthesis by these hormones and is not 
linked to estrogen directly.
2-10 BRCA1-BRCA2 INTERACTIONS
It is known that germline mutations in the putative tumor suppressor gene, 
BRCAl predispose women to an elevated risk of breast cancer. Like BRCAl, germline 
mutations in the structurally unrelated gene BRCA2 predispose women to breast cancer. 
However germline mutations in BRCA2 also predispose male carriers to an increased 
risk of breast cancer (Thorlacius et a i, 1995). In addition BRCA2 mutations are also 
found in tumor types other than breast, including pancreas, prostate and colon 
(Thorlacius et al., 1996). Recent studies have shown a relation between the expression 
of BRCAl and BRCA2 (Rajan et a i, 1996). In 1996 Rajan et a l, analyzed the 
relationship between Brca2 expression and mammary epithelium cell proliferation and 
differentiation. Results indicated that Brca2 mRNA expression was down-regulated in 
response to serum deprivation, and up-regulated in rapidly proliferating and/or 
differentiating mammary epithelial cells, peaking at the Gl/S boundary in a cell-cycle 
dependent manner during proliferation. The same pattern of expression was also
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observed for Brcal suggesting that regulation of Brca2 mRNA expression occurs 
coordinately with Brcal and the expression is tightly regulated during mammary 
epithelium proliferation and differentiation. And, as these two genes are coordinately 
expressed during proliferation and/or differentiation of mammary epithelial cells, it is 
very possible that Brcal and Brca2  may function in overlapping regulatory pathways. 
(Rajan et a l, 1997). Their results also indicated that the up-regulation of Brcal and 
Brca2 expression during the differentiation of mammary epithelial cells occurs by a 
proliferation-independent pathway, because when the post confluent mammary epithelial 
cells were induced for differentiation, an increased expression of both Brcal and Brca2  
was observed (Rajan et al., 1996).
2-11 BRCAl HOMOLOGUES
Studies with the homologues of tumor suppressor genes from other species 
provide valuable informations about the biochemical features of the protein. Especially 
mouse, provides a good system for the characterization of the roles of these genes and 
other events take part during neoplastic transformation, as their genetic background can 
be controlled easily.
Comparison of human BRCAl with the murine sequence revealed 72% identity 
at the nucleic acid level (Marquis ei al., 1995), and 73% similarity and 58% identity at 
the amino acid level. Mouse Brcal is located on chromosome 11 and encodes an 1812 
amino-acid protein (Abel et al., 1995). The mouse homolog also contains a RING finger 
domain near the amino terminus, and a conserved highly acidic domain in the carboxyl 
terminus.
49
CHAPTER 111
AIM AND STRATEGY
Identification of function of genes requires the presence of purified protein 
products. Therefore this study was directed towards the production and purification of 
BRCAl encoded proteins. For this reason, we designed a project, in order to express 
and purify the BRCAl encoded proteins. The first step of the project involves the 
cloning of the BRCAl gene in four overlapping fragments into the cloning vector pCR- 
Script Amp SK(+). We planned to divide BRCAl into four fragments for two reason. 
First in order to minimize mutations in the amplification step due to DNA polymerase 
mistakes, and second it is hard to produce large proteins in E. coli. The second part of 
the project involves the subcloning of these fragments into the expression vector pQE. 
As approximately 90% of mutations of BRCAl result in the formation of truncated 
protein products lacking the carboxyl terminal and the presence of the BRCT domain in 
this region, we planned express the B4 fragment. The other three fragments of BRCAl 
Bl, B2, and B3 will also be subcloned to pQE and expressed in future.
A general outline of the experiments performed in this study is shown in figure 3-1.
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We have designed to clone BRCAl in four overlapping fragments (Bl, B2, B3, 
and B4). All the fragments of BRCAl were amplified by using Pfu DNA polymerase. 
Pfii DNA polymerase was preferred because of the enzyme's high fidelity and in order to 
generate blunt ended products. Schematic representation of the amplified regions is 
shown in figure 3-2. In all PCR reactions BRCAl cDNA (pLXSN-BRCAl) was used as 
template and the reactions products were run on 1% agarose gel at lOOV.
3-1 Amplification of BRCAl fragments
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Figure 3-2: Schematic representation of the amplified fragments of BRCAl
The primers for the amplification of four BRCAl fragments were designed such 
that each fragment contains a Bam HI site at its 5 prime (5') end and a Hind III site at its 
3 prime (3') end. Also, the overlapping regions of the fragments contain restriction 
enzyme cutting sites that are known to cut BRCAl only once (Bal I site at nucleotide
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1414, Sea I site at nucleotide 3267, and Bam HI site at nucleotide 4058). These unique 
sites can be used to join two fragments in the future studies.
3-2 Cloning of the amplified fragments into pCR-Script Amp SK (+) vector
Each Pfu amplified blunt-ended PCR product was purified and cloned into the 
predigested pCR-Script vector. Epicurian coli cells were transformed with the pCR- 
Script-BRCAl plasmids.
3-3 Subcloning of the B4 fragment into pQE-31
pCR-Script-BRCAl/B4 plasmid was digested with Bam HI and Hind III and the 
B4 fragment was taken out. As BRCAI also has a Bam HI site at nucleotide position 
4058, the internal Bam HI site was utilized instaed of the Bam HI site in the forward 
primer in order to put B4 in frame. B4 fragment was found to be in frame when pQE-31 
was used. Therefore, pQE-31 was also digested with Bam HI and Hind III and the B4 
fragment was cloned into pQE-31. A schematic representation of the cloning proedure is 
shown in figure 3-3.
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EcoRI/RBS 6xHis
pQE-31 A T G A G A G G A T C G  I AC GGATCC T  TTC T T  CCTAGGAAAGAAC j
Bam HI
B4.
Hind III
GGAT'
B4 fragment
ACn’GACTGC -f.-v;/;'-, -■^ {^ '^■¿-'■{aGCTT|— PQE 31
CGCATGCGAGCTCGGTACCCCGGGTCGACCTGCAGCCA
Bam W  Hind IH digestion 
cuts out this region
Figure 3-3 ; Cloning into pQE 31
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CHAPTER IV
MATERIALS AND METHODS
4-1 Polymerase chain reaction (PCR)
Polymerase chain reaction had been used during this study in order to amplify the 
human BRCAl gene. The requirements for PCR are listed below (Saiki et al., 1988). 
Pfii DNA polymerase was used to catalyze the reaction because Pfli DNA polymerase 
exhibits the lowest error rate of any thermostable DNA polymerase (1.3 x 10·^ ). 
Comparison of the fidelities of different thermostable DNA polymerases are listed in 
table 4-1. Pfu DNA polymerase is a proofreading enzyme with 3' ^  5' exonuclease 
activity, that generates blunt-ended PCR products. The buffer conditions were described 
by the supplier.
1- Template DNA with known flanking sequences
2 - Oligonucleotides with homologous sequences to that of the template flanking 
region (primers)
3- DNA polymerase and appropriate buffer
4- Deoxynucleotide triphosphates
5- Temperature cycling machine
A standard 1 0 0  ul reaction set up in a 0.2 ml PCR tube
primers 0.1-1 uM of each primer (reverse and forward) 
dNTP 0.2 mM diluted from the 10 mM stock
buffer 1X diluted from the 1 OX stock
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template 10 ng of genomic or plasmid DNA
Made up to 1 0 0  ul with MilliQ water
enzyme 2.5 unit of Pfii DNA polymerase
Each reagent and tube were placed on ice. To perform a hot-start PCR the 
thermal cycler was preheated to approximately 90^0 before placing the tubes into it.
Table 4-1: Fidelity comparison of thermostable DNA polymerases
Thermostable DNA polymerases Error rate Mutated PCR products
(x 1 0 -6 ) (%)
Pfu DNA Polymerase 1.3 2 . 6
Taq DNA Polymerase 8 . 0 16.0
Vent DNA Polymerase 2 . 8 '  5.6
Deep Vent DNA Polymerase 2.7 5.4
Tfl DNA Polymerase 8.3 16.6
n r  DNA Polymerase 9.5 19.0
UlTma DNA Polymerase 55.3 1 1 0 .6
List of the synthetic oligonucleotide primer sets used in this study are summarized in 
table 4-2.
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Table 4-2 List of the synthetic oligonucleotide primer sets used in this study
name of the
primer
sequence size Tm (OC)
BRCIFI CggATCCTggATTTATCTgCTCTTCgC 27 65
BRCIRI TAAgCTTAgCCTCATgAggATCACTgg 27 60
BRC1F2 CggATCCgAggTAgATgAATATTCTgg 27 61
BRC1R2 gAAgCTTCATTAgTACTggAACCTAC 26 51
BRC1F3 CggATCCggAACATTCAATgTCACCTg 27 67
BRC1R3 gAAgCTTAATTCCTTgTCACTCAgACC 27 57
BRC1F4 CggATCCgAATTggAAgACTTgACTgC 27 65
BRC1R4 TAAgCTTCAgTAgTggCTgTgggggg 25 61
4-2 Purification of PCR products
Purification of PCR products were done either as described below or by the MBI 
DNA extraction kit (#K0513).
PCR products were purified by precipitating the DNA with ammonium acetate. 
1/10 volume of lOX STE buffer, equal volume of 4M ammonium acetate and 2.5 
volume of 100% (v/v) ethanol were added to the PCR products sequentially. The 
reaction tube was centrifugated at 13000 rpm for 2 0  minutes at room temperature to 
pellet DNA. The supernatant was removed carefully and discarded. The pellet was 
washed with 2 0 0  ul of 70% (v/v) ice-cold ethanol. The pellet was dried and DNA was 
resuspended by using TE buffer.
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Agarose, which is extracted from seaweed is a linear polymer. Charged 
molecules like DNA or RNA became oriented in an electric field and migrate towards 
the attracting pole of the field. Such charged polymeric molecules are also capable to 
migrate within the porous structure of a linear polymer, like agarose. These properties of 
DNA and RNA were abused to qualitatively and quantitatively analyze nucleic acids. In 
the presence of a good electrolitic buffer and an electric field, nucleic acids migrate 
towords cathode through the linear pores of polymerized agarose. The seperation 
capacity of such gels depend on the agarose content. Range of seperation in gels 
containing different amount of agarose is summarized in table 4-3.
Table 4-3 : Range of seperation in gels containing different amount of agarose
4-3 Horizontal electrophoresis of DNA
Amount of agarose in the gel (%w/v) Efficient range of seperation of linear 
DNA molecules(kb)
0.3 5-20
0 . 6 1 - 2 0
0.7 0 .8 - 1 0
0.9 0.5-7
1 .2 0.4-6
1.5 0.2-3
2 . 0 0 .1 - 2
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Generally ТАЕ and ТВЕ buffers were used to define a conductive medium. 
These buffers have their best electrolytic ability when used as 0.5-IX solutions. Contents 
of these buffers are summarized in table 4-4.
Table 4-4 : Commonly used electrophoresis buffers
Buffer Working solution Concentrated stock 
solution (per liter)
Tris-aceta te (TAE) IX: 0.04M Tris acetate 
O.OOIM EDTA
50X: 242 g Tris base 
57.1 ml Glacial acetic 
acid
100 mi of 0.5 M EDTA
Tris-borate (TBE) 0.5X: 0.045M Tris borate 
O.OOIM EDTA
5X: 54 g Tris base 
27.5 g boric acid 
20 mi of 0.5 M EDTA
Agarose is added at desired amount of 0.5-1 X of electrophoresis buffer 
(volume adjusted with dH2 0 ) and the slurry mixture is heated until it gets transparent. 
The gel apparatus must be set before and the wells that DNA will be inserted must be 
defined with combs that were provided with the gel apparatus. After pouring and 
solidification, the gel is ready to be placed in a tank filled with the same running buffer 
and ready for DNA to be inserted to the holes provided by the comb. A steady voltage 
of 50-100V is applied to the buffer and the tank is frequently checked for overheating. It 
is of importance to consider the place of holes in the gel and the direction of the voltage 
since DNA will run from (-) to (+). Visualization of DNA in the gels could be achieved
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by soaking the gel in ethidium bromide solution (lOug/ml) and staining for 10 minutes. 
The DNA could be viewed under UV light.
4-4 DNA ligation
DNA fragments, that were cut from agarose gel and recovered by MBI DNA 
extraction kit (#K0513) were used for ligation. For forced cloning (where both vector 
and insert DNA has protruding ends) approximately 1:4 ratio of vector and insert DNA 
was mixed with the T4 DNA ligase buffer and 1 to 3 units of T4 DNA ligase. The 
reaction is carried out either 2  hours at room temperature or 16 hours at 12°C. For blunt 
end ligation insertivector ratio could be increased up to 40 and preferably the reactions 
must be accomplished at 12*^ C. The reaction could be stopped directly by heating at 
650C for 1 0  minutes or directly used to transform competent bacterial cells.
4-5 Bacterial strains and their growth and storage
4-5.1 Bacterial strains and media
4-5.1.1 Strains of E .coli: Strains of Kcoli used in this study are summarized in table 4-5.
4-5.1.2 Solid and liquid mediums :
LB medium : 0.5% Yeast extract, 1% Bacto-tryptone, 1% NaCl.
LA medium : 0.5% Yeast extract, 1% Bacto-tryptone, 1% NaCl and 1% agar. 
Supplemented with appropriate antibiotics.
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Table 4-5 : Strains of E.coli used in this study
Strain genotype usage reference
M15
(pREP4)
Nal s Str s r if  s la c  arar gal· 
mil· F" uvr'  ^ recA
Host for 
expression
Villajero and 
Zabin(1974)
Epicurian 
coli XLl- 
Blue 
MRF' 
Kan
A(/wcrA)183 A(/ncTCB-/í5í/SMR- 
m rr)n 3  endAl supE44 thi-l 
recAl gyrA96 relAX lac
supercompetent
cell
Host for plasmid
Stratagene
(#200248)
JM 109 F> troD35 lacH A{lacZ)m \5  
proABIrecAX endAX gyrA96 
{Nal·) thi hsdR17(r^w+j^) 
supE44 e l4" (mcrA~) relAXA(lac- 
proAB)
propagation of 
the vector (pQE)
Stratagene
4-5.1.3 Antibiotics
Ampicilin and kanamycin were used in this study (Table 4-6).
6 1
Table 4-6: Concentrations of the antibiotics used in this study
Stock solution working concentration
name of concentration storage stringent relaxed
the plasmids plasmids
antibiotic
Ampicilin 50 mg/ml in H^O -20«C 2 0  ug/ml 60 ug/ml
Kanamycin 1 0  mg/ml in H9O - 200c 1 0  ug/ml 50 ug/ml
4-5.2 Growth and storage of bacterial strains 
4-5.2.1 Growth of E. coli strains
All strains were grown in liquid culture in LB medium and on LA medium 
supplemented with the appropriate antibiotics.
4-5.2.2 Storage of E.coli strains
Strains of E.coli were stored in glycerol (long term storage). Glycerol cultures of 
E.coli were prepared by adding 0.81 ml of fresh culture to 0.91 ml of sterile 80% 
glycerol in a sterile screw capped tube. The tubes were vortexed and were then frozen 
and stored at -70°C.
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4-6 Cloning and subcloning of BRCAl fragments 
4-6.1 Cloning strategies
4-6.1.1 pCR Script Amp SK (+) cloning plasmid
pCR Script Amp SK (+) cloning plasmid was supplied with the pCR-Script Amp 
SK (+) cloning kit of Strategene (# 211190). The pCR-Script vector is a 2961 bp 
plasmid, derived from the pBluescript II SK (+) phagemid. This cloning vector includes 
an ampicilin-resistance gene, a lac promoter for gene expression, T3 and T7 RNA 
polymerase promoters for in vitro production of RNA, an fl intergenic region for single- 
stranded DNA (ssDNA) rescue, the SK multiple cloning site, which is modified to 
include the srf I restriction-endonuclease target sequence and five conveniently located 
sequencing primer sites. This vector ideally works with blunt-ended PCR products. The 
map of pCR Script Amp SK (+) cloning plasmid is shown in figure 4-1.
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Figure 4-1: Map of the pCR Script Amp SK (+) cloning plasmid 
4-6.1.2 pQE expression vectors
The pQE plasmids belong to the pDS family of plasmids and were derived from 
plasmids pDS56/RBSII and pDS781/RBSII-DHFRS. They contain the following 
elements:
A regulable promoter/operator element (consisting of the E.co// phage T5 
promoter and two lac operator sequences), a synthetic ribosome binding site (RBSII), 
6 xHis affinity coding sequence, a multi-cloning site, translation stop codons in all three 
reading frames, the transcriptional terminator 'to' from phage lambda and the replication 
region and the gene for P-lactamase of plasmid pBR322. A map of the pQE vector is 
shown in figure 4-2.
The pQE expression vectors were preferred as they provide high-level expression 
of proteins or peptides containing a 6 xHis affinity tag in E.coli. The tag may be placed at
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the N-terminus of the protein (Type IV constructs), C-terminus of the protein (Type III 
construct) or at the C-terminus of the protein utilizing its original ATG start codon, to 
create a type ATG construct. If the peptide that is going to be expressed is a short 
peptide, mouse DHFR can be fused to the peptide to create type II construct (figure 4- 
3). The type IV constructs are the most commonly used constructs as they are often 
expressed 2-4 times more efficiently than the type III constructs. In this study type IV 
constructs were used. Type IV constructs also have three different types, pQE30, 
pQE31 and pQE32, each designed to have different reading frames for the expression of 
the protein inframe (figure 4-2).
Xhol
Figure 4-2: pQE vector
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Type IV
6 xHis
Type III
Type III 
ATG
Type II
6 xHis
DHFR
6 xHis
6 xHis
Figure 4-3: Different pQE constructs
EcoRI/RBS 6xHis multiple cloning site to
pQE-30 ATG A G A G G A T C t · · · ·  - - I ....... :....I A A T T A G C T G A G I^
EcoRI/RBS 6xHis multiple cloning site to
pQE-31 ATG AG AG G ATCtM BBBAC t ------1 AATTAGCTGAGES3
EcoRI/RBS 6xHis multiple cloning site
pQE-32 atg agaggatc( C = b - n
to
] AATTAGCTGAGE121
Bam HI Sph I Sac I Kpn I Xma I Sal I Pst I Hind III
GGATCCGCATGCGAGCTCGGTACCCCGGGTCGACCTGCAGCCAiiGCTT
Figure 4-4 :Type IV constructs
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Expression is regulated by the pREP4 repressor plasmid which carries the lac/ 
and the kanamycin resistance gene and is present in M l5 strain oiE.coli. Expression 
from pQE vectors is induced by the addition of IPTG, which inactivates the repressor 
and clears the promoter.
The 6 xHis tag allows the protein to be purified by the usage of Ni-NTA resin. 
The NTA ligand has four chelating sites which can interact with metal ions. NTA 
occupies four of the six ligand binding sites in the coordination sphere of the Ni^+ ion, 
leaving two sites free to interact with the 6 xHis tag. This interaction between the 6 xHis 
tag and Ni-NTA resin permits the purification of proteins at approximately 99% purity.
4-6.2 Growth of plasmids in transformed bacteria
Double stranded DNA was manipulated by the introduction of plasmid vectors 
into bacterial host cells. The existence of ampicilin and/or kanamycin resistance gene in 
each of these vectors was exploited to select the transformed .bacterial cells during 
growth of bacterial cultures.
Bacterial cells transformed with plasmid vectors were streaked onto LBagar 
plates supplemented with the antibiotics at indicated concentrations in table 4-5 and 
grown overnight at 37®C in the inverted position. A single bacterial colony was 
transferred into 5 ml LB broth containing the appropriate concentration of the antibiotic 
by using a sterile loop, and rotated at 37®C overnight.
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Cells were made competent using a modification of the CaClj method described 
by Maniatis ei al., 1982.
5 ml LB was inoculated using a single colony from a freshly grown plate of the 
E. coli strain to be used, and was incubated at ЪІ^С for approximately 2 hours, until the 
culture was slightly turbid. The culture was then cooled on ice for 5 minutes, 1 ml 
aliquots were added to microcentrifuge tubes and then the cells were pelleted by 
centrifugation (1 minute at 13,000 rpm ). The cells were resuspended in 0.5 ml of 50 
mM CaCljby gentle vortexing, before being placed on ice for 30 minutes. The cells were 
pelleted by centrifugation (1 minute at 13,000 rpm ), and the supernatant was discarded. 
The pellet was resuspended in 0 .1 ml of СаСІ2 with gentle vortexing. The cells were then 
stored on ice until required for transformation. Alternatively competent cells were 
prepared and stored at -70®C until required. 500 ml of LB was seeded with a 10 ml of 
overnight culture and grown to an 0 .6 . Cells were harvested by centrifugation at
5000 rpm for 10 minutes at 4®C, before being incubated on ice for 2 0  minutes. The cells 
were harvested as before, resuspended in 25 ml of 50 mM СаСІ2 /20% glycerol and 
aliquoted into microcentrifuge tubes before being frozen. Samples were stored at -70°C 
and were viable for at least 2  months. Cells were thawed on ice prior to the addition of 
DNA.
50 mM СаСІ2
73.5gCaCl2.2H2O  
Add H2O to 100 ml
Filter sterilized using a disposable filter, or autoclaved.
4-7 Preparation of competent cells
6 8
The DNA to be transformed (usually a lul of ligation mixture or approximately 
100 ng of plasmid DNA) was added to the 100 ul of competent cells, mixed gently and 
incubated on ice for 30 minutes. The cells were then heat-shocked at 42®C for 90 
seconds and chilled by placing on ice for 2  minutes. 1 ml of prewarmed LB was then 
added and the suspension was incubated at 37®C for 1 hour. Each sample was pelleted 
by centrifugation at 13,000 rpm for 2 minutes, resuspended in 100-200 ul of LB and 
plated onto selective medium and incubated overnight at 37®C to allow the growth of 
the transformants.
If the vector-host system used featured a-cornplementation of P-galactosidase to 
enable for blue/white selection of recombinants, then 25 ul of a 20 mg/ml stock solution 
of X-Gal (5-Bromo-4-chloro-3-indolyl-P-D-galactoside) in dimethylformamide and 20 ul 
of a 2 0  mg/ml stock solution of IPTG (Isopropylthio-P-o-galactoside) in dHjO were 
added to the agar plates prior to spreading the cells. If the host-was DHSaMCR then 
IPTG was omitted, since this strain lacks the lac repressor and hence expression from 
Plac promoter is constitutive.
4-9 Small scale preparation of plasmid DNA (Mini-preparation)
This protocol is based on the alkaline lysis method of Birnboim and Doly (1979).
The transformed bacterial strain containing the plasmid of interest was grown at 
37^C overnight in 5 ml of LB-i-antibiotic. 1.5 ml of the bacterial culture was pelleted by 
centrifugation for 1 minute (bench-top microfiige, 13,000 rpm) in a 1.5 ml microfuge 
tube. After the discartion of the supernatant, the cells were resuspended in 0.1 ml of ice- 
cold solution I and stored for 5 minutes at room temperature. 0.2 ml of solution II was 
mixed by inversion, the tube was then stored on ice for 5 minutes. Bacterial
4-8 Transformation of bacterial ceils
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chromosomal DNA and proteins were precipitated by the addition of 0.15 ml of ice-cold 
solution III. The mixture was left on ice for 5 minutes, then centrifugated in a bench-top 
centrifuge for 5 minutes to pellet the host DNA and proteins. The supernatant was 
mixed with an equal volume of phenol-chloroform ( 1 ; 1) and centrifugated in a bench-top 
microfuge for 3 minutes to separate the two phases. The top phase was removed and 
plasmid DNA precipitated by mixing it with 2.5 volumes of 95% ethanol, and pelleted by 
centrifugation for 10 minutes (bench-top microfuge, 13,000 rpm) after keeping the 
mixture at 4®C for 15 minutes. The supernatant was discarded and the pellet was left for 
15-20 minutes at room temperature to dry and then resuspended in 20-30 ul of TE 
buffer containing 1 0  ug/ml RNase A. Samples were stored at 4°C.
This procedure yields approximately 3 ug of DNA.
Solution 1
50 mM glucose 
25 mM Tris-Cl (pH 8 .0 ) 
lOmMEDTA (pH 8.0)
Solution I can be prepared in batches of approximately 100 ml, autoclaved for 15 
minutes at 1 0  Ib/square in. on liquid cycle, and stored at 4^0.
Solution II
0.2 NaOH (freshly diluted from 10 N stock)
1% SDS
Solution III
5 M potassium acetate 
glacial acetic acid
60 ml 
11.5 ml 
28.5 ml
The resulting solution is 3 M with respect to potassium and 5 M with respect to acetate.
H^O
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TE buffer
pH 7.4 lOmMTris Cl (pH 7.4)
ImMEDTA (pH 8.0)
pH 7.6 lOmMTris Cl (pH 7.6)
ImM EDTA (pH 8 .0 )
pH 8.0 lOmMTrisCl (pH 78.0)
ImMEDTA (pH 8.0)
4-10 Purification of plasmid DNA using Wizard tips (Midiprep)
All midi-preparations were carried out by using the kit supplied by Promega 
(Catalog number: A7510)
4-11 Purification of plasmid DNA by equilibrium centrifugation in caesium 
chloride-ethidium bromide gradients (Maxi-preparation)
4-11.1 Preparation of large scale bacterial culture
The bacterial strain containing the plasmid of interest was first grown in a 30 ml 
culture with necessary antibiotic until late log phase (OD5 QQ of 0 .6 ) then inoculated into 
500 ml LB or Terrific Broth medium for 10-12 hours (2.5 ml of a solution of 
chloramphenicol (34 mg/ml in ethanol) could be added when OD5 Q0  of 0.4 is reached in 
order to increase the yield from low copy number plasmids ). The cells were harvested 
by centrifugation at 4000 rpm for 15 minutes at 4®C in a Sorvall GS3 rotor (or 
equivalent). The supernatant was discarded and allow to drain away in a upside down 
position. Cell were resuspended in 100 ml of ice cold STE.
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0.1 MNaCl
10 mM Tris.Cl(pH:8.0)
1 mM EDTA(pH;8.0)
Cells were collected again by centrifugation as described above.
4-11.2 Lysis by alkali
This protocol is based on the alkaline lysis method of Bimboim and Doly (1979) 
and the solutions were described above in the mini preparation section.
The bacterial pellet was resuspended and washed in 18 ml solution I (in the presence of 
chloramphenicol cells should be resuspended in 1 0  ml and the instructions in parentheses 
should be followed).
- 2 ml (1 ml) of freshly prepared solution of lyso2yme was added ( 1 0  mg/ml in 10 mM 
Tris.Cl (pH;8 .0 ) )
- 40 ml (20 ml) of freshly prepared solution II was added , the top of centrifuge tube was 
closed and the bottle was inverted several times. The bottle was kept at room 
temperature for 5-10 minutes.
- 20 ml (15 ml) of ice cold solution III was added, the top of the bottle was closed and 
shaked several times. The bottle was stored on ice for 10 minutes.
- The cell lysate was centrifuged at 4000 rpm for 15 minutes at 4®C. The rotor must stop 
without braking.
- The supernatant was filtered through 4 layers of cheesecloth into a 250 ml centrifuge 
bottle. 0 . 6  volume of isopropanol was added and mixed well, in order to precipitate the 
nucleic acids. The bottle was kept at room temperature for 10 minutes.
- Nucleic acids were recovered by centrifugation at 5000 rpm for 15 minutes at room 
temperature in a Sorvall GS3 rotor (or equivalent). Salt may precipitate if the
STE :
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centrifugation is performed at 4°C. The supernatant was poured off gently and the 
bottle was inverted so as to allow all fluid to drain away. The pellet and the walls of the 
bottle was washed with 70% ethanol at room temperature. After draining off ethanol, by 
the help of a pasteur pipette attached to vacuum, beads of liquid that were attached to 
the walls of the bottle were removed. The inaccessible ethanol was left to evaporate at 
room temperature. The pellet was dissolved in 3 ml of TE (pH 8.0) and become ready 
for centrifugation in CsCl-ethidium bromide gradients.
4-11.3 Purification of closed circular DNA by equilibrium centrifugation in CsCI- 
ethidium bromide gradients
The volume of the DNA solution must be measured exactly and for every 
milliliter, 1 g of solid CsCl must be added to the solution. It is feasible to warm the 
solution to 30®C to allow easy dissolution of the salt. The mixture was centrifuged at 
8000 rpm for 5 minutes in order to separate the proteins complexed with ethidium 
bromide and pure nucleic acids. The clear red solution at lower phase contains nucleic 
acids and must be transferred to a Beckman Quick seal tube or equivalent. For this 
process, a disposable syringe could be used. It is very important to seal the centrifuge 
tube correctly and not to overload the tube. The density gradients were centrifuged at 
80000 rpm for 16 hours at 20®C. Two bands appear after centrifugation in the center of 
the gradient and upper band contains the linear bacterial chromosome and nicked plasmid 
DNA, whereas the lower and thicker band corresponds to the circular plasmid DNA. The 
deep red pellet at the bottom of the tube consists of ethidium bromide-RNA complexes. 
For the collection of DNA bands, first a 21-gauge hypodermic needle was inserted into 
the top of the tube to allow air to enter. For minimizing the possibility of contamination, 
first the upper band was collected. The surface of the tube was cleaned with ethanol and 
a piece of Scotch Tape was attached to the outside of the tube. An 18-gauge hypodermic
73
needle was inserted just below the upper band and the upper band was collected. As 
collection was finished, the needle was plugged and a second needle was inserted just 
below the lower band of DNA and the viscous solution was collected. The ethidium 
bromide must be removed from the DNA solution by extracting at least 6 times an equal 
volume of isoamyl alcohol. The DNA must also be cleared away from CsCl so the final 
solution of DNA is diluted with 3 volumes of water and 2 volumes of ethanol (total 
volume is 6X of the original) and precipitated by centrifugation at lOOOOg for 15 
minutes at 4®C. This method yields 1-5 mg of plasmid DNA.
4-12 Quantification of double strand DNA
The amount of DNA in samples were determined by reading the absorbency of 
the samples at 260 nm. An OD260 of 1 corresponds to a concentration of 50 ug/ml for 
double stranded DNA, 40 ug/ml for single stranded DNA and 20 ug/ml for 
oligonucleotides (Maniatis et al., 1982).
4-13 Restriction analysis of plasmid DNA
DNA restriction reactions were carried out in a total volume of 20-100 ul with 5- 
10 units of restriction enzyme, lul of boiled RnaseA (Img/ml) was used where 
appropriate. The volume of the reaction buffers were arranged to be IX and the enzyme 
volume was never greater than 1/10th of the reaction volume so as to prevent star 
activity due to the high glycerol concentration.
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Protein purification can be done under denaturing and non-denaturing 
conditions.
4-14.1 Small scale protein purification under denaturing conditions :
Bacteria harboring expression plasmid was cultured overnight in 5-10 ml LB with 
adequate selection of antibiotic. Induction of the cells were done with 0.4-2 mM IPTG 
for 5 hours. Cells were harvested by centrifugation at 20000 rpm for 2 minutes. The cell 
pellet was dissolved in 2 ml of buffer B.
The suspension was vortexed in order to lyse the cells. During this step frothing 
should be avoided. The suspension get clear when lysis was complete. The sample 
quickly loaded to the column prepared and equilibrated before.
4-14.1.1 Preparation and equilibration of the column
The column was prepared from a 10 ml syringe. The opening of the syringe was 
plugged with cotton glass and wetted with dH20. 200-400 ul 50% Ni-NTA agarose was 
placed into the column (It is very important not to plug very much glass cotton that 
could prevent flow of the fluids by gravitational force.). After allowing the Ni-NTA 
agarose to settle, 2 ml of buffer B was added and allowed to flow by gravity. It is very 
important not to allow the column dry, so as the flow ends, 200 ul of buffer B was 
placed into the column and the opening of the column was plugged. The column was 
equilibrated in this position for 30 min. at room temperature before loading.
4-14 Induction of expression, lysis of bacteria and purification of proteins
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100 ul aliquot was taken from total lysate (named fraction 1) and kept at -20®C 
for SDS-PAGE analysis of proteins. The rest of the total lysate was loaded on the pre­
equilibrated column. The fluid let flow by gravity. 6xHis tagged proteins were supposed 
to bind the column and the rest of the proteins were supposed to flow down and produce 
the second fraction named; flowthrough. Washing the column 3 times with 2 ml of buffer 
C was essential to remove any unspecific bound proteins from the column. These 
elutions gained as a result of the 3 washes were called fractions 3,4 and 5. Finally the 
6xHis tagged proteins were removed from the column by 1 ml of buffer D (named 
fraction 6).
If desired all the proteins that bind the column could be eluted with strip buffer 
(named fraction 7), which removes the Ni'^ ··' ions from the column so the proteins bound 
the ions. It is of importance that the stripped columns can not be used again.
The fractions can be analyzed by SDS-PAGE protein electrophoresis.
Buffer A :
8 M Urea
300 mM NaCl
50 mM NaH2P0 4
Buffer B . same as buffer A but the overall pH of this buffer is adjusted to 8.0 
with HCl.
Buffer C : Same as buffer A but pH adjusted to 6.3 with HCl.
Buffer D : Buffer C containing 400 mM imidazole.
Strip buffer : 0.1-0.5 M EDTA pH : 8.0
4-14.1.2 Loading and purification of the sample
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100 ul of bacteria which had been inoculated from a colony on agar plate 
harboring the expression vector was inoculated into 20 ml of LB media including the 
appropriate antibiotic and incubated overnight at 37°C. The concentration of antibiotic 
could be increased in order to minimize the plasmid loss. 10 ml of this culture was then 
used to inoculate 500 ml of fresh LB media+antibiotic. Bacteria were grown until the 
absorption at 600 nm reach 0.7-0.9. IPTG is added to a final concentration of 2 mM and 
incubation was further continued for 5 hours.
Cells were harvested by spinning at 5000 rpm for 10 minutes at 4°C, supernatant 
was discarded. The pellet was resuspended in 5-volumes of solubilization buffer and 
homogenized in the homogenizer for 5 times of 90 second periods. It is very important 
to keep the samples on ice between each homogenization to avoid protein degradation.. 
Samples were left on a rotative shaker in a refrigerated room for 20 minutes. An aliquot 
of 0.5 ml was taken, and soluble and insoluble fractions were separated by centrifugation 
at 15,000 rpm for 5 minutes at 4®C. Both fractions were kept at -70OC. The remaining 
suspension was treated with liquid nitrogen and 37°C iteratively (freeze-thaw) 5 times. 
An aliquot of 0.5 ml was taken, and soluble and insoluble fractions were separated by 
centrifugation at 15,000 rpm for 5 minutes at 4®C. Both fractions were kept at -70®C. 
The remaining suspension was sonicated in ice cold water for 2 minutes. An aliquot of 
0.5 ml was taken, and soluble and insoluble fractions were separated by centrifugation at 
15,000 rpm for 5 minutes at 4®C. Both fractions were kept at -70®C. The remaining 
suspension was centrifugated at 4®C for 10 minutes at 13,000 rpm. The supernatant and 
the pellet was freezed down to -70®C.
4-14.2 Large Scale Protein purification under non-denaturing conditions
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Preparation of the column was described above in 'small scale purification of 
proteins under denaturing conditions' section, but since this is a large scale purification, 1 
ml of 50% Ni-NTA agarose is placed in the column and equilibrated with 2  ml of 
solubilization buffer without lysozyme (Buffer 2).
4-14.2.2 Loading and purification of the sample
2.5 ml of supernatant from the supernatant was applied to the column and 
allowed to flow with gravity. This fraction was named as flowthrough and the 6 -His 
tagged proteins were supposed to bind the column. The column was washed 2 times with 
buffer 2 and 1 times with buffer 3. The wash steps produced the fractions W l, W2 and 
W3 and supposed to clear all the non-specific bindings, whereas the 6 -His tagged 
proteins were supposed to retain. The elution of tagged proteins were done in 2 steps, 
eluting with 300 ul of buffer 4 and 300 ul of buffer 5. The fractions obtained as total 
lysate, flowthrough, W l, W2, W3 and buffer 4 and buffer 5 could be run in a SDS- 
PAGE gel.
The Ni-NTA Spin Kit was also used for the purification of proteins. (# AW
96003)
Buffer 1 (Solubilization Buffer)
50 mM Sodium phosphate (NaH2P0 4 ) pH: 8  
300 mM Sodium Chloride (NaCl)
Img/ml lyzozyme (freshly added)
Buffer 2
50 mM Sodium phosphate (NaH2P04) pH: 8
4-14.2.1 Preparation and equilibration of the column
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зоо тМ  Sodium Chloride (NaCl)
Buffer 3
Buffer 2 with 20mM imidazole 
Buffer 4
Buffer 2 with 250mM imidazole 
Buffer 5
Buffer 2 with 500mM imidazole
4-15 SDS-Polyacrylamide gel electrophoresis of proteins
The glass plates were assembled according to the manufacturer's instructions 
(BioRad). The volume of the gel mold was determined according to the information 
provided by the manufacturer (BioRad). In an Erlenmeyer flask, the appropriate volume 
of solution containing the desired concentration of acrylamide for the resolving gel was 
prepared. Effective range of separation of SDS-PAGE gels due*to different acrylamide 
concentrations are summarized in table 4-7 and concentrations of components of the 
resolving gel at different concentrations are summarized in table 4-8.
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Table 4-7 Effective range of separation of SDS-PAGE gels:
Acrylamide concentration (% Linear range of separation (kP)
15 12-43
10 16-68
7.5 36-94
5.0 57-212
Without delay, the mixture was swirled rapidly and the acrylamide solution was 
poured into the gap between the glass plates. Sufficient space (the length of the teeth of 
the comb plus 1 cm.) for the stacking gel was left. The acrylamide solution was 
overlayed by using a pasteur pipette with 0 . 1  % SDS (for gels containing <8 % 
acrylamide) or isobutanol (for gels containing > 1 0 % acrylamide). The gel was placed in 
a vertical position at room temperature. After polymerization was complete, the overlay 
was poured off and the top of the gel was washed several times with deionised water to 
remove any unpolymerized acrylamide. As much fluid as possible was drained from the 
top of the gel and then any remaining water was removed with the edge of a paper 
towel.
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Table 4-8 Solution of preparing resolving gels for Tris-glycine SDS-PAGE
Solution
components
Component Volumes (ml)
6% 5 ml 10 ml 15 ml 20 ml 25 ml 30 ml 40 ml 50 ml
(IH7O 2 . 6 5.3 7.9 1 0 . 6 13.2 15.9 2 1 . 2 26.5
30% mix 1 . 0 2 . 0 3.0 4.0 5.0 6 . 0 8 . 0 1 0 . 0
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 1 0 . 0 12.5
10% SDS 0.05 0 .1 0.15 0 . 2 0.25 0.3 0.4 0.5
10% APS 0.05 0 . 1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
TEMED 0.004 0.008 0 . 0 1 2 0.016 0 . 0 2 0 0.024 0.032 0.040
8%
-
dH ,0 2.3 4.6 6.9 9.3 11.5 13.9 18.5 23.2
30% mix 1.3 2.7 4.0 5.3 6.7 8 . 0 10.7 13.3
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 1 0 . 0 12.5
10% SDS 0.05 0 . 1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
10% APS 0.05 0 .1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
TEMED 0.003 0.006 0.009 0 . 0 1 2 0.015 0.018 0.024 0.030
10%
dH^O 1.9 4.0 5.9 7.9 9.9 11.9 15.9 19.8
30% mix 1.7 3.3 5.0 6.7 8.3 1 0 . 0 13.3 16.7
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 1 0 . 0 12.5
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10% SDS 0.05 0 . 1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
10% APS 0.05 0 .1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
TEMED 0 . 0 0 2 0.004 0.006 0.008 0 . 0 1 0 0 . 0 1 2 0.016 0 . 0 2 0
12%
dH^O 1 . 6 3.3 4.9 6 . 6 8 . 2 9.9 13.2 16.5
30% mix 2 . 0 4.0 6 . 0 8 . 0 1 0 . 0 1 2 . 0 16.0 2 0 . 0
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 1 0 . 0 12.5
10% SDS 0.05 0 . 1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
10% APS 0.05 0 . 1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
TEMED 0 . 0 0 2 0.004 0.006 0.008 0 . 0 1 0 0 . 0 1 2 0.016 0 . 0 2 0
15%
dH,P 1 .1 2.3 3.4 4.6 5.7 6.9 9.2 11.5
30% mix 2.5 5.0 7.5 1 0 . 0 12.5 15.0 2 0 . 0 25.0
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 1 0 . 0 12.5
10% SDS 0.05 0 . 1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
10% APS 0.05 0 . 1 0.15 0 . 2 0 0.25 0.30 0.40 0.50
TEMED 0 . 0 0 2 0.004 0.006 0.008 0 . 0 1 0 0 . 0 1 2 0.016 0 . 0 2 0
Stacking gel was prepared in a disposable plastic tube at an appropriate volume 
and at desired acrylamide concentration. Concentrations of components of the resolving 
gel at different concentrations are summarized in table 4-9. Without delay, the mixture 
was swirled rapidly and the stacking gel solution was poured directly onto the surface of 
the polymerized resolving gel. The comb was immediately inserted into the stacking gel,
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being carefiil to avoid trapping air bubbles. The gel was placed in a vertical position at 
room temperature. While the stacking gel was polymerizing, the samples to be loaded 
were prepared by heating them to lOO^C for 3 minutes in IX SDS gel-loading buffer to 
denaturate the proteins. After polymerization was complete, the comb was removed 
carefully. By using a squirt bottle, the wells were washed with deionized water to 
remove any unpolymerized acrylamide.
Table 4-9 Solution of preparing 5% stacking gels for Tris-glycine SDS-PAGE
Solution
components
Component Volumes (ml)
5% gel 1 ml 2 ml 3ml 4 ml 5 ml 6 ml 8 ml 10 ml
dH:,0 0 . 6 8 1.4 2 . 1 2,7 3.4 4.1 5.5 6 . 8
30% mix 0.17 0.33 0.50 0.67 0.83 1 .0 1.3 1.7
1.0 M Tris 
(pH 6.8)
0.13 0,25 0.38 0.50 0.63 J0.75 1 .0 1.25
10% SDS 0 . 0 1 0 . 0 2 0.03 0.04 0.05 0.06 0.08 0 . 1
10% APS 0 . 0 1 0 . 0 2 0.03 0.04 0.05 0.06 0.08 0 . 1
TEMED 0 . 0 0 1 0 . 0 0 2 0.003 0.004 0.005 0.006 0.008 0 . 0 1
The gel was mounted in the electrophoresis apparatus. Tris-glycine
electrophoresis buffer was added to the top and bottom reservoirs. The bubbles that 
were trapped at the bottom of the gel between the glass plates were removed by a bent 
hypodermic needle attached to a syringe. 1 0 0 - 2 0 0  ug of protein was loaded in a 
predetermined order into the wells. The electrophoresis apparatus was attached to an
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electric power supply and the gel was run at a voltage that is approximately 8 V/cm, 
After the dye front has moved to the resolving gel, the voltage was increased to 15 
V/cm, until the bromophenol blue reaches the bottom of the resolving gel. Then the 
power supply was turned off
The glass plates were removed from the electrophoresis apparatus and placed on 
a paper towel. By using a spatula, the plates were pried apart. Orientation of the gel was 
marked by cutting a comer from the bottom.
IX SDS gel-loading buffer
50 mM Trie Cl (pH 6 .8 ) 
lOOmM dithiothreitol (DTT)
2% SDS (electrophoresis grade)
0 .1% bromophenol blue 
1 0 % glycerol
IX SDS gel-loading buffer lacking DTT can be stored at room temperature. 
DTT should be added, just prior to use, from 1 M stock.
Tris-glycine electrophoresis buffer 
25 mM Tris
250 mM glycine (electrophoresis grade)
0 .1% SDS
30% mix (Acrylamide and bis-acrylamide solution)
A stock solution of 29% (w/v) acrylamide and 1% (w/v) bis-acrylamide. Solution 
was stored in dark bottles at 4®C.
10% SDS
A 10% (w/v) stock solution was prepared in deionized water 
APS
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A small amount of 10% stock solution was prepared in deionized water and 
stored at 4^0.
4-16 Transfer of proteins from SDS-polyacrylamide gels to solid supports
As the SDS-polyacrylamide gel was approaching the end of its run, six pieces of 
Whatman 3MM paper and one piece of transfer membrane (Millipore-Immobilon-P) was 
cut to the exact size of the SDS-SDS-polyacrylamide gel by wearing gloves because oil 
and secretions from the skin may prevent the transfer of proteins from the gel. Matching 
of the sizes of these papers and transfer membrane is very important because if the paper 
or membrane is larger than the gel, the overhanging edges of the paper and the 
membrane will touch the charged plates, causing a short circuit that will prevent the 
transfer of protein from the gel. One comer of the membrane was marked with a soft- 
lead pencil.
The membrane was left in methanol for 5 minutes and then washed with 
deionized water and soaked into transfer buffer for 15-20 minutes. Meanwhile the 
Whatman 3MM papers were soaked into a shallow tray containing a small amount of 
transfer buffer and kept shaking for 15-20 minutes.
Wearing gloves, the transfer apparatus was set as follows:
- 3 layers of Whatman 3MM paper that have been soaked in transfer buffer was 
put onto the plate which will be negatively charged (cathode). It is important to squeeze 
out any air bubbles.
- The transfer membrane was placed onto the Whatman 3MM papers. (The 
transfer membrane should be exactly aligned and the air bubbles trapped between it and 
the Whatman 3MM paper should be squeezed o u t.)
- The glass plates holding the SDS-polyacrylamide gel was removed from the 
electrophoresis tank, and the gel was transferred to a tray of deionized water.
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- SDS-polyacrylamide gel was placed onto the transfer membrane. Any trapped 
air bubbles were squeezed out with a gloved hand.
- 3 layers of Whatman 3MM paper were placed to the top of the sandwich (this 
side will be positively charged during the transfer (anode side).)
The upper plate of the apparatus which will be the cathode during the transfer. 
The electrical leads of the apparatus were connected to the power supply and the 
transfer was carried out at a current of 0.65 mA/square. cm of the gel for a period of 
1.5-2 hours.
The electric current was turned of at the end of the run time and the transfer 
apparatus was disassembled from top downward, peeling off each layer in turn. The gel 
was transferred to a tray containing Coomassie Brilliant Blue and stained in order check 
if the transfer is complete or not. The bottom left-hand corner of the membrane was cut 
as insurance against obliteration of the pencil mark.
4-17 Staining SDS-polyacrylamide gels with Coomassie Brilliant Blue
Polypeptides separated by SDS-polyacrylamide gels were fixed with 
methanol;glacial acetic acid and stained with Coomassie Brilliant Blue R250.
0.25 g of Coomassie Brilliant Blue R250 was dissolved in 90 ml of 
methanol:H2 0  (1:1 v/v) and 10 ml of glacial acetic acid. In order to remove any 
particulate material, the solution was filtered through a Whatman No. 1 filter. The gel 
was immersed in at least 5 volumes of staining solution and was placed on a slowly 
rotating platform for a minimum of 4 hours at room temperature.
At the end of staining, the stain was removed and saved for future use. The gel 
was destained by soaking in the methanol-acetic acid solution without the dye (90 ml of 
methanol:H2 O ( 1 :1  v/v) and 1 0  ml of glacial acetic acid), on a slowly rotating platform 
for 4-8 hours at room temperature, changing the destaining solution three or four times.
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destaining for 24 hours allows as little as 0.1 ug of protein to be detected as a single 
band.
After destaining, gels can be stored indefinitely in water or can be dried.
4-18 Staining proteins immobilized on solid surfaces with Ponceau S
The membrane onto which proteins were transferred was washed with deionized 
water and then soaked into Ponceau S. When bands of proteins become visible, the 
membrane was washed in several changes of deionized water at room temperature. The 
positions of proteins used as molecular-weight standards were marked.
Ponceau S
1 0 % glacial acidic acid 
5% Ponceau S 
dH20
4-19 Immunological detection of immobilized proteins (Western Blotting)
After staining the proteins immobilized on transfer membrane with Ponceau S, 
the membrane was washed gently with deionized water and neutralized with the 
blocking buffer for 5 minutes. In order to inhibit non-specific binding sites, the 
membrane was immersed in the blocking solution for at least 30 minutes. We used the 
mouse monoclonal antibody from Calbiochem (#OP94). Primary antibody was diluted as 
recommended by the supplier in blocking solution and was kept at room temperature for 
at least one hour on a slowly rotating platform. Afterwards the membrane was washed 
for three times, once for 15 minutes and twice for 5 minutes, with blocking buffer.
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Following the washes the membrane was incubated in the blocking solution containing 
the secondary antibody (peroxidase-conjugated rabbit anti-mouse immunoglobin- 
DAKO) diluted as recommended by the supplier for 1 hour and then washed for three 
times, once for 15 minutes and twice for 5 minutes, with the blocking buffer. Finally the 
membrane was washed with deionized water and become ready for development.
Blocking Buffer
0 . 1  % Tween- 2 0  in IX PBS 
Blocking Solution
5% milk powder in 0 .1% Tween 20-PBS solution
IX PBS
8  g NaCl
0 . 2  g KCl
1.44 g Na2HP04
0,24 g KH2PO4
Volume was adjusted to 1 liter
pH was adjusted to 7.4
4-20 Detection of proteins immobilized on membranes by using the ECL Western 
Blotting kit (Amersham Life Science) (Catalog no: RPN 2106)
Detection of proteins immobilized on membranes were done by using the ECL 
Western Blotting kit (Amersham Life Science) (Catalog no; RPN 2106)
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CHAPTER V
RESULTS
5-1 Introduction
Results are explained in the following order;
> Amplification of BRCA1 fragments by PCR
> Cloning of BRC A1 fragments into pCR-Script Amp SK(+) cloning vector
> Plasmid DNA isolation be miniprep
> Confirmation of the positive clones by restriction enzyme analysis
> Maxiprep of the pQE vectors
> Subcloning of B4 into the pQE-31 vector
> Plasmid DNA isolation be miniprep
> Confirmation of the positive clones by restriction enyme analysis
> Conformation of the expression and purification of BRCAl C-terminal (B4) 
encoded polypeptide by Western Blotting
Results of the restriction enyme analysis are shown following the miniprep 
results for each fragment.
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5-2 Amplification of BRCAl fragments
The names of the primers and the region that they amplify are shown in table 5-1 
and the schematic representation of the amplified regions is shown in figure 5-2.
Table 5-1: Names of the primers and the regions that they amplify
name of the 
primer
name of the 
fragment
amplified region 
(nt)
length of the 
fragment
amplified region 
(aa)
BRCFl-BRCRl Bl 121-1436 1316 bp 1-439
BRCF2-BRCR2 B2 1371-3286 1915 bp 419-1052
BRCF3-BRCR3 B3 3131-4138 1008 bp 1005-1341
BRCF4-BRCR4 B4 4023-5711 1688 bp 1301-1863
The PCR conditions used during the amplification reactions are listed below:
Bl: 95®C for 7 min.; (95®C for 1 min.; 56®C for 1 min.; 72°C for 3.00 min) x 35; 
720C for 10 min.; 4^C
B2: 95®C for 7 min.; (95°C for 1 min.; 56^0 for 1 min.; 72°C for 4.30 min.) x 35; 
720Cfor 10 min ; 4 0 c
B3 : 9 5 0 c  for 7 min.; (95®C for 1 min.; 560C for 1 min.; 72^C for 2.46 min.) x 35; 
720C for 10 min.; 4^C
B4: 9 5 0 c  for 7 min.; (950C for 1 min.; 57®C for 1 min.; 72^C for 3.30 min.) x 35; 
72^C for 10 min.; 4®C
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The results of the PCR reactions are shown in figure 5-1 and 5-2.
1 2 3 4 5
1915 bp 
1008 bp
Figure 5-1: Amplification results of the second (B2) and third (B3) fragments of 
BRCAl
(Lane 1: B3; Lane 2: B3 negative control; Lane 3; 123 bp DNA ladder (Sigma); Lane 
4: B2; Lane 5: B2 negative control; Lane 6; 1 kb DNA ladder); (7 ul of 50 ul)
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1688 bp ______ ^
1316 bp ______ ►
______2000 bp
-^--------1630 bp
1000 bp
Figure 5-2: Amplification results of the first (Bl) and fourth (B4) fragments of 
BRCAl
(Lanel; 1 kb DNA ladder; Lane 2: B l ; Lane 3; Bl negative control; Lane 4; B4;
Lane 5: B4 negative control; Lane 6: 123 bp DNA ladder); (7 ul of 50 ul)
The expected lengths of the PCR products are shown in table 5-1. Amplification 
reactions resulted in the production of BRCAl fragments of the expected length with 
the absence of non-specific bands, indicating the accuracy of the PCR conditions. As 
control, the same reactions were carried out in the absence of template DNA in order to 
show that the bands are not the results of any contamination.
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5-3 Cloning of the 4 different PCR fragments of BRCAl into the pCR-Script 
cloning vector
The amplified BRCAl fragments were purified and inserted into the pCR-Script 
Amp SK(+) cloning vector (Stratagene, #211190). The Pfu amplified, blunt ended PCR 
products were incubated with the predigested cloning vector, the restriction enzyme Srf 
I (1 ul from 5 U/ul stock) and T4 DNA ligase (1 unit from 4U/ul stock). Both enzymes 
were supplied by Strategene. Srf is a rare cutter that specifically cuts from the 
GCCC/GGGC sequence to generate blunt ended products. Usage of the restriction 
enzyme in the ligation reaction maintained a high-steady state concentration of the 
digested vector.
The cloning procedure is summarized in figure 5-3.
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Srf 1 site
insert T4 ligase
S rfI
T4 DNA ligase
insert
Figure 5-3: A summary of the ligation protocol 
5-4 Minipreps of plasmid DNA
Following the transformation of the ligation products into the Epicurian Coli 
XL 1-Blue MRF' Kan supercompetent cells (Stratagene), the positive clones were 
selected on the basis of blue/white selection on IPTG - X-Gal LB-agar plates. The 
IPTG-Xgal LB-Agar plates were prepared by spreading 40 ul of 2% X-Gal (dissolved in 
dimethylformamide) and 25 ul of 100 mM IPTG (dissolved in dH20) 1 hour before the 
inoculation of bacteria, as IPTG can be toxic to cells if it is not absorbed by the LB-agar. 
The white colonies were the ones harboring the insert and the blue color indicates the
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absence of the insert because in such colonies lacZ gene is still intact and the IPTG in 
the medium induces this gene to produce P-galactosidase. P-galactosidase in the medium 
uses X-gal, and this reaction results in the formation of blue color.
Plasmids in the supercompetent cells were purified by using the miniprep 
technique explained in the materials and methods section.
The plasmids with the insert were expected to run slower on 1% agarose gel. 
The results of the minipreps are shown in figures 5-4, 5-5, 5-11, 5-13, 5-15.
5-5 Restriction analysis of plasmid DNA
Presence of the fi'agment of interest in the plasmid was confirmed by restriction 
analysis. All the reactions were carried out by using 300-500 ng of plasmid DNA and 5- 
10 U of each enzyme, in the appropriate buffer.
The results of the reactions are shown in figures 5-6, 5-7, 5-10, 5-12, 5-14, 5-16.
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1 2
5000 bp 
3000 bp
2000 bp 
1500 bp
Figure 5-4: Miniprep result of the clones that are expected to carry the first 
fragment (Bl)
(Lane 1: 1 kb DNA ladder (MBI), Lane 2 : Bl-clone5, Lane 3 : Bl-clone 6, Lane 4 ; 
Bl-clone 7); (4 ul of 25 ul)
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5000 
3000 bp ---------- ^
2000 bp ---------- ►
1 5 0 0 ----------- ►
1000 bp
Figure 5-5; Miniprep result of the clones that are expected to carry the first 
fragment (Bl)
(Lane 1: 1 kb DNA ladder (MBI), Lane 2: Bl-clone 6, Lane 3: Bl-clone 8, Lane 4; 
Bl-clone 9, Lane 5; Bl-clone 10, Lane 6; Bl-clone 11, Lane 7 : Bl-clone 12); (4 ul of 
25 ul)
As the shift of the bands indicate the presence of the insert, among the 13 clones 
tested, only two of them were said to be positive (clones 6 and 11). The bands seen at 
smaller lengths indicate the presence of different conformations of plasmid DNA, 
occurred due to the alkaline treatment of DNA in the second step of the DNA 
purification.
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5000 b p _____ ^
4000 b p --------►
3000 bp --------►
2000 bp --------►
Figure 5-6 : Restriction enzyme digestion of the DNA obtained from the minipreps 
of the clones carrying the first fragment (Bl)
(Lane 1; 1 kb DNA ladder (MB I), Lane 2 : Bl-clone 6- Hind III cut. Lane 3 : Bl- 
clone 1-Hind III cut. Lane 4 : Bl-clone 11- BamHI cut) (10 ul reaction volume loaded)
The digestions of the plasmid DNA obtained from clones 1, 6 and 11, showed 
that the shift in the run pattern of DNAs indicate the presence of the insert in the 
plasmids. Clone number 1 was used as a negative control. As expected, vector without 
the BRCAl fragment run approximately at 3000 bp (2961 bp) and the vectors with the 
insert run approximately at 4000 bp (4277 bp).
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5000 bp 
3000 bp
1500 bp 
1000 bp
Figure 5-7 : Restriction enzyme digestion of the DNA obtained from the 
minipreps of the clones carrying the first fragment (Bl)
(Lane 1: 1 kb DNA ladder. Lane 2 ; Bl-clone 6- Hind III cut. Lane 3 : Bl-clone 6- 
Hind III and BamHI cut. Lane 4 ; Bl-clone 11- Hind III cut. Lane 5 ; Bl-clone 11- 
Hind III and BamHI cu t); (10 ul reaction volume loaded)
As a result of this experiment two bands were expected. The different digestion 
patterns of the two clones indicate that the BamHI site of the first fragment was 
somehow lost and that the fragments were inserted in opposite orientations into the 
vector, as shown in figure 5-8. The presence of the insert was further confirmed by 
digesting the vector with Sal I and Sea I (Figure 5-9). These two enzymes cut only from 
the multiple cloning site of the vector and the first fragment of BRCAl do not have the 
recognition sites for these enzymes. Results of these digestions are shown in figure 5-10.
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Hindin Bam H f BamHI Hindin
BamHI 
Hind III
BamHI
Hindin
B 1 done 6 (lostBamHI site) done 11
BamHI
Hindin
BamHI
Hindin
I I i .  \
Hindin BamHI Hind III
I IHindin Hindin
BamHI Hindin
Figure 5-8 : The two orientations of the B1 insert in pCR-Script doning vector.
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B1 fragment 
1316 bp
Figure 5-9: The Sac I and Sal I restriction sites on the pCR-Script cloning vector.
( If the insert is present length of the digestion product will be: 1316+85=1401 bp and 
when this region is digested out length of the remaining vector will be 2961-85=2876 
bp)
4000 bp 
3000 bp
2000 bp 
1500 bp
Figure 5-10 : Digestion of the DNAs obtained from clones B l-6 and Bl-11 with 
Sac 1 and Sal I
(Lane 1; 1 kb DNA ladder (MBI), Lane 2: B1-clone 6, Lane 3: B1-clone 11), (10 ul 
reaction volume loaded)
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The results of this digestion proved that both of the clones carry the vectors that 
carry the B1 fragment. Uncut DNA was expected to run at 4277 bp and two other 
fragments were expected one at 1401 bp and the other at 2876 bp. The band of 4277 bp 
represents the uncut plasmid.
1 0 2
A-
1 2  3 4 5
5000 bp
3000 bp ----------- ^
2000 bp ----------- ►
1500 bp ----------- ►
B-
50001^  
3000 bp
2000 bp 
1500 bp
3 4 5 6 7 8
Figure 5-11 : Miniprep result of the clones that are expected to carry the second 
fragment (B2)
A;(Lane 1; 1 kb DNA ladder (MBI), Lane 2: B2-clone 1, Lane 3: B2-clone 2, Lane 4; 
B2-clone 3)
B;(Lane 1: 1 kb DNA ladder (MBI), Lane 2; empty, Lane 3: B2-clone 4, Lane 4; B2- 
clone 5, Lane 5: B2-clone 6, Lane 6: B2-clone 7, Lane 7; B2-clone 8, Lane 8: B2- 
clone 9); (4 ul of 25 ul)
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Five of the nine clones (clones 1, 2, 3, 5 and 6) were thought to be positive and 
digested by Bam HI and Hind III.
A:
5000 bp 
3000 bp 
2000 bp 
1500 bp
1000 bp
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B;
5000 bp 
3000 bp 
2000 bp 
1500 bp
1000 bp
Figure 5-12 : Restriction enzyme digestion of the DNA obtained from the 
minipreps of the clones carrying the second fragment (B2)
A;(Lane 1: 1 kb DNA ladder (MBl), Lane 2; B2-clone-l- Hind III and BamHI cut. 
Lane 3; B2-clone 1 uncut-control)
B:(Lanel: 1 kb DNA ladder (MBI), Lane 2: B2-clone-2, Lane 3; empty, Lane 4: B2- 
clone 4-Hind III and BamHI cut. Lane 5: B2-clone 6-Hind III and BamHI cut. Lane 6: 
B2-clone 6-uncut-control); (10 ul reaction volume loaded)
Results of the restriction enzyme digestion showed the presence of B2 harboring 
plasmid in the colonies indicated above.
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1 2 3 4 5 6 8 9 10 11
5000 bp _ 
3000 bp - 
2000 bp 
1500 bp
Figure 5-13 : Miniprep results of the clones that are expected to carry the third 
fragment (B3)
(Lane 1: 1 kb DNA ladder (MBI), Lane 2: empty vector-control, Lane 3: B3-clone 1, 
Lane 4: B3-clone 2, Lane 5: B3-clone 3, Lane 6; B3-clone 4, Lane 7; B3-clone5, 
Lane 8: empty, Lane 9: 1 kb DNA ladder (MBI), Lane 10: B3-clone 6. Lane 11: B3- 
clone 7, Lane 12: 1 kb DNA ladder (MBI)); (4 ul of 25 ul) -
Comparison of the lengths of DNA fragments in lanes 3, 4, 5, 6, 7, 10, and 11 
with the empty plasmid control in lane 2, suggested that all the clones were positive. 
Restriction enzyme analysis of the positive fragments with Hind III and Bam HI showed 
that the insert was B3.
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3000 bp 
2 0 0 0  bp
1 0 0 0  bp 
500 bp
Figure 5-14; Restriction enzyme digestion of the DNA obtained from the 
minipreps of the clones carrying the third fragment (B3)
(Lanel: 1 kb DNA ladder (MBI), Lane 2: B3-clone 1, Lane 3: B3-clone 2, Lane 4: 
B3-clone 3, Lane 5: B3-clone 4, Lane 6: B3-clone 5, Lane 7: B3-clone 6, Lane 8: B3- 
clone 7, Lane 9: 1 kb DNA ladder (MBI); (10 ul reaction volume loaded)
Results of the restriction enzyme digestion showed the presence of B3 harboring 
plasmid in the colonies indicated above.
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5000 bp 
3000 bp 
2 0 0 0  bp 
1500 bp
Figure 5-15: Miniprep results of the clones that are expected to carry the fourth 
fragment (B4)
(Lane 1: 1 kb DNA ladder (MBI), Lane 2 and 3: control minipreps , Lane 4: B4-clone 
1, Lane 5: B4-clone 2, Lane 6; B4-clone 3, Lane 7: B4-clone 4, Lane 8: B4-clone 5); 
(4 ul of 25 ul)
Results of the miniprep indicated that all of the five clones are harboring 
plasmids with an insert and in order to show that the insert is B4, the plasmids were 
digested with Bam HI and Hind III.
1 0 8
1 2 3 8
1000 bp
5000 b p -----------►
3000 b p -----------►
Figure 5-16: Restriction enzyme digestion of the DNA obtained from the 
minipreps of the clones carrying the fourth fragment (B4)
(Lanel; 1 kb DNA ladder (MBI), Lane 2; B4-clone 1, Lane 3; B4-clone 2, Lane 4: 
B4-clone 3, Lane 5: B4-clone 4, Lane 6: B4-clone 5); (10 ul reaction volume loaded)
Restriction enzyme digestion of the positive fragments with Bam HI and Hind 111 
showed that the insert was B4.
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5-6 Purification of plasmid DNA by equilibrium centrifugation in caesium 
chloride-ethidium bromide gradients (Maxiprep)
The maxipreps of the pQE expression vectors were done as described in the materials 
and methods section. All three types of the pQE vectors: pQE 30, 31 and 32 were first 
amplified in the host JM109 and then following the miniprep (figure 5-17) and 
restriction analysis (figure 5-18), the vectors were purified in large quantities by 
maxiprep.
The DNA yield was about 2 ug/ul (total 2 mg DNA). The results of the 
maxipreps are shown in figure 5-19.
6  7 8 9 10 11
3000 bp
Figure 5-17 : Miniprep results of the clones that are expected to carry the PQE 
vectors(Lane 1: 1 kb ladder (MBI), Lane 2: empty, Lane3: pQE 30, Lane 4: pQE 30, 
Lane 5: pQE 30, Lane 6 pQE 31, Lane 7; pQE 31, Lane 8: pQE 31, Lane 9: pQE 32, 
Lane 10: pQE 32, Lane 11: pQE 32); (4 ul of 25 ul)
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The expected uncut size of pQE was expected to be approximately 2500 bp, (cut size is 
3460 bp).
1 2
3500 bp
4 5 6 7 8
Figure 5-18 : Restriction enzyme analysis of the DNA obtained from the minipreps 
of the clones carrying the pQE vector.
(Lane 1: 1 kb ladder (MBI), Lane 2: pQE 30, Lane3; pQE 30, Lane 4; pQE 30, Lane 
5: pQE 31, Lane 6: pQE 31, Lane 7: pQE 32, Lane 8: pQE 32); (10 ul reaction 
volume)
IIJ
3000 bp
Figure 5-19 :ResuIts of the maxipreps
(Lane 1: 1 kb ladder (MBI), Lane 2; pQE 30 maxiprep, Lane3: pQE 30 miniprep. Lane 
4; pQE 31 maxiprep. Lane 5; pQE 31 miniprep, Lane 6: pQE 32 maxiprep. Lane 7: 
pQE 32 miniprep)
These results indicated the presence of a pure and high yield DNA without RNA 
contamination.
5-7 Subcloning of the C-terminal of BRCAl into the expression vector pQE
The C-terminal region of BRCAl (B4) was subcloned into pQE31. For this 
purpose the DNA extracted from pCR-Script-B4 harboring cells by midiprep was 
digested with Bam HI and Hind III enzymes in order to cut out the B4 fragment (Figure 
5-20) and the B4 fragment was recovered by eluting the band of interest from 1% 
agarose gel. Similarly pQE31 was digested with the two enzymes and the vector was 
eluted from 1% agarose gel by using the MBI DNA extraction kit (# K05132). The 
ligation and transformation reactions were carried out as described in the materials and 
methods section. For transformation. Ml 5 cells were used, as these cells contain another 
plasmid coding for the repressor (prep4). After transformation cells were grown in LB- 
medium containing both ampicilin and kanamycin.
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Presence of the B4+pQE31 in Ml 5 cells were shown by miniprep and restriction 
enzyme digestion, (figure 5-21 and figure 5-22)
3000
1500
1000
Figure 5-20 : Restriction enzyme digestion of B4+pCR-Script vector with Bam HI 
and Hind IH.
(Lane 1: 1 kb marker (MBI), Lanes 2 and 3: control digestions. Lanes 4 and 5: B4 
Bam HI and Hind III cut. Lanes 6 and 7: control digestions. Lane 8: (^ DNA/ EcoRI- 
Hind III-MBI).
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51931^
Figure 5-21 : Miniprep results of the clones that are expected to carry the 
B4+PQE31 vector
(Lane 1: (X DNA/Eco RI- Hind III digest-MBI), Lane 2-5; control minipreps. Lane 6- 
8: B4 in pQE)
1 2 3  4 5  6 7 8 9  10 11
4973 bp --------- ►
3530 b p ---------
2027 b p ______ ^
1904 bp----------- ►
1584 bp----------- >■
-^-------- 5149 bp
,,______3461 bp
16S8bp
Figure 5-22 : Restriction enzyme digestion of B4+pQE31 vector with Bam HI and 
Hind IH.
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(Lanes 1-2: (X. DNA/Eco RI- Hind III digest-MBI), Lanes 3-8; control digestions. Lane 
9; B4 in pQE 31- Bam HI cut, Lane 10: B4 in pQE 31- Bam HI-Hind III cut. Lane 11: 
pQE31)
5-8 Western blotting
The pQE+B4 harboring Ml 5 cells were grown and induced, and the protein 
(carboxyl terminal of BRCAl) was purified as described in the materials and methods 
section. Induction of the B4 fragment was shown by loading the non-induced and 
induced samples to the gel (figure 5-23). Although most of the protein content in the cell 
was found to be insoluble (5-24), a small-scale purification was performed under 
denaturating conditions and a large-scale purification was performed under non- 
denaturating conditions. Western blot analysis of the proteins with the BRCAl antibody, 
BRCAl-3 (#OP94) revealed a purified band at 73 IcD (figure 5-25).
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73 Kd
Figure 5-23 : Induced and non-induced samples
(Lane 1; molecular weight marker, Lane 2: prestained molecular weight marker. Lane 
3; C-terminal of the BRCA2 protein (E7)-non-induced, Lane 4: C-terminal of the 
BRCA2 protein (E7)-induced, Lane 5: B4-non-induced, Lane 6: B4-induced, Lane 7: 
p53 non-induced. Lane 8: p53 induced)
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BRCA2 fragments and p53 were used as negative controls, for the specificity of 
the antibody. Presence of the bands only in lane6 indicated that the expression of the B4 
fragment was induced by IPTG and that the antibody BRCAl-3 do not cross-react with 
any of the tested proteins.
12 13 14 15
Figure 5-24 : Soluble and the insoluble fractions of the protein
(M: molecular weight marker (lanes 1 and 15), M: prestained molecular weight marker 
(lane 2); P=insoluble fraction; S/N+soluble fraction)
1J7
For non-denaturating purification of the proteins, cells were lysed in three steps. 
E71 P, E71-S/N, B41 P and B41-S/N represent the samples obtained as a result of 
homogenizing the samples for 5 times; E72 P, E72-S/N, B42 P and B42-S/N represent 
the samples obtained as a result of ffeeze-thaw; and finally E73 P, E73-S/N, B43 P and 
B43-S/N represent the samples obtained as a result of ultrasonification. The results 
indicated that the most efficient way of lysis was freeze-thaw. The band seen in lane 12 
in figure 5-25 was interpreted as an artifact.
73 kD
Figure 5-25 ; Purified BRCAl C-terminal protein (1)
(M; molecular weight marker (lanel), M: prestained molecular weight marker 
(lane 15); Lanes 2-6 ; the samples obtained from the purification performed by using the 
Quigen Ni-NTA resin kit ; lane 7; total lysate; and lanes 8-14 ; the samples obtained
m
from the purification performed as explained in materials and methods section.)
These results indicated that the protein was most efficiently eluted by 250 mM 
imidazole. The wash steps in the second part of the gel (lanes 9-11) were performed with 
20 mM imidazole and this amount of imidazole is believed to wash away all the non­
specific bindings.
73 kD
Figure 5-26 : Purified BRCAl C-terminal protein (2)
(M: molecular weight marker (lanel))
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These results indicated that the protein was most efficiently eluted by 250 mM 
imidazole and that usage of 20mM imidazole elutes all the non-specific bindings 
supporting the results of the previous experiment.
UQ
CHAPTER VI
DISCUSSION AND FUTURE PERSPECTIVES
The BRCAl gene and its protein product have been the subjects of intensive 
investigation because of its important role in human breast and ovarian cancers. In spite 
of numerous studies conserning the regulation of BRCAl expression and the function of 
its protein products, there are still lots of unknowns.
BRCAl gene is composed of 22 coding exons which are transcribed into 7.8 kb 
transcript (Miki et al.,). Identification of shorter transcripts, indicates the presence of 
alternative splicing (Lu et ah, 1996); (Xu et al., 1995). Alternative splicing may play 
significant roles in modulating the biological functions of a number of proteins. Some 
splice variants of BRCAl were shown to lack exon 11 which harbors two important 
nuclear localization signals. Absence of nuclear localization signals results in the 
cytoplasmic localization of the protein. Thus, presence of different BRCAl transcripts 
encoding proteins with different motifs, may play a significant role in modulating the 
subcellular localization and therefore the physiological functions of BRCAl.
BRCAl was found to be 220 kD phosphoprotein that is phosphorylated in a cell 
cycle dependent manner. Many line of evidence indicated that BRCAl is a tumor 
supressor gene. Recently identified BRCT domain in the BRCAl protein suggested that 
BRCAl may be involved in DNA repair. It has also been identified that BRCAl 
expression was very during proliferation and differentiation.
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All these data suggest different roles for BRCAl. Thus the exact function of 
BRCAl remains to be elucidated. Therefore, this study was directed towards the 
construction of expression vectors, that produce different regions of BRCAl.
In this study we planned to optimize a strategy in order to express and purify 
BRCAl encoded proteins in E.coli as purified proteins are needed for such studies. For 
this purpose we have chosen the carboxyl terminal of the protein. Carboxyl terminal of 
the protein emerges as the most important region of BRCAl as 90% of mutations of the 
BRCAl gene results in premature translation. Also the presence of the BRCT motif in 
this regions confers further importance to this region.
Future studies will include the expression and purification of the other three 
fragments of BRCAl (Bl, B2, and B3), which are already present in the cloning vector 
pCR-Script Amp SK (+). It will also be possible to join these fragments with each other 
by using the single cutter sites present in the overlapping regions and thus produce 
larger proteins. It will also be possible to produce antibodies against each of the 
fragment and if desired against the combinations of the fragments. Production of 
antibodies against small fragments of BRCAl will provide more specificity to the 
antibody, such that we will be able to know the region of the BRCAl which is 
recognized by that particular antibody.
Antibodies are important and useful tools in molecular biology. Many cellular 
localization studies of BRCAl were carried out by using polyclonal and monoclonal 
antibodies. One of the essential features of antibodies is the specificity of the antibody. 
Usage of antibodies that cross-react with other proteins in a cell may give rise to false 
positive results as in the case of granin expectations of BRCAl (Chen et al., 1995).
Presence of purified protein products will also be useful in studies conserning the 
identification of different functional domains of the BRCAl encoded proteins.
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APPENDIX
The DNA ladders used in this study.
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